

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Evaluating the impact of using mobile vaccination units to increase COVID-19 vaccination uptake: A synthetic control analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071852
Article Type:	Original research
Date Submitted by the Author:	15-Jan-2023
Complete List of Authors:	Zhang, Xingna; University of Liverpool, Department of Public Health, Policy & Systems Tulloch, John; University of Liverpool, HPRU EZI Knott, Shane; Liverpool Liverpool City Council Allison, Rachel; Russells Hall Hospital Parvulescu, Paula; Liverpool City Council Buchan, Iain; University of Liverpool, Public Health and Policy Garcia-Finana, Marta; University of Liverpool, Department of Health Data Science; Clinical Trials Research Centre, Piroddi, Roberta; University of Liverpool, Department of Public Health, Policy & Systems Green, Mark; University of Liverpool, Geography & Planning Baird, Sophie; The UK Health Security Agency Barr, Ben ; University of Liverpool, Department Public Health and Policy
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Evaluating the impact of using mobile vaccination units to increase COVID-19 vaccination**
4 **uptake: A synthetic control analysis**
5

6 Xingna Zhang¹, John Tulloch², Shane Knott³, Rachel Allison⁴, Paula Parvulescu⁵, Iain Buchan⁶, Marta
7 García-Fiñana⁷, Roberta Piroddi⁸, Mark A. Green⁹, Sophie Baird¹⁰, Ben Barr¹¹
8

9 ¹ Research Associate, Department of Public Health, Policy & Systems, University of Liverpool,
10 Liverpool, UK
11

12 ² Tenure Track Fellow, Department of Livestock and One Health in the Institute of Infection,
13 Veterinary and Ecological Science, University of Liverpool, Liverpool, UK
14

15 ³ Senior Public Health Practitioner (Healthcare), Liverpool City Council, Liverpool, UK
16

17 ⁴ FY1 Doctor, Russells Hall Hospital, Dudley, UK
18

19 ⁵ Consultant in Public Health Medicine, Liverpool City Council, Liverpool, UK
20

21 ⁶ Chair in Public Health and Clinical Informatics, Department of Public Health, Policy & Systems,
22 University of Liverpool, Liverpool, UK
23

24 ⁷ Professor of Health Data Science, Department of Health Data Science, University of Liverpool,
25 Liverpool, UK
26

27 ⁸ Research Fellow, Department of Public Health, Policy & Systems, University of Liverpool, Liverpool,
28 UK
29

30 ⁹ Reader in Health Geography, Department of Geography & Planning, University of Liverpool,
31 Liverpool, UK
32

33 ¹⁰ Public Health Registrar, The UK Health Security Agency, UK
34

35 ¹¹ Chair in Applied Public Health Research, Department of Public Health, Policy & Systems, University
36 of Liverpool, Liverpool, UK
37
38
39
40
41

42 Corresponding author:

43 Xingna Zhang

44 xingna.zhang@liverpool.ac.uk
45

46
47 WORD COUNT (excluding title page, abstract, figures, tables, references, author statements and
48 appendices): 3306
49

50 No of Tables (excluding Appendix): 2
51

52 No of Figures (excluding Appendix): 3
53

54 Supplementary files: 4 appendices at the end of this document
55
56
57
58
59
60

ABSTRACT

Objective To assess the impact on COVID-19 vaccine uptake of mobile vaccination units; vaccine provision that is temporally introduced into a neighbourhood using a large vehicle such as a bus or 'pop-up clinic'. We further investigate whether such an effect differed by deprivation, ethnicity and age.

Design Synthetic control analysis.

Setting The population registered with General Practices in nine local authority areas in Cheshire and Merseyside in the Northwest of England.

Intervention Mobile vaccination units that visited 37 sites on 54 occasions between 12th April and 28th June 2021. We defined populations as having received the intervention if they lived within 1km of a mobile vaccination site. A weighted combination of neighbourhoods that had not received the intervention was used to construct a synthetic control group.

Outcome The weekly number of first-dose vaccines received among people aged 18 and over as a proportion of the population.

Results The introduction of a mobile vaccination unit into a neighbourhood increased the number of first vaccinations conducted in the neighbourhood by 25% (95% CI: 21% to 28%) within three weeks after the first visit to a neighbourhood, compared to the synthetic control group. This effect was smaller amongst 30–65-year-olds compared to 18-30-year-olds, amongst Asian and Black ethnic groups compared to White ethnic groups, and the most socioeconomically deprived populations compared to the least deprived areas.

Conclusions Mobile vaccination units are effective interventions to increase vaccination uptake, at least in the short-term. While mobile units can be geographically targeted to reduce inequalities, we found evidence that they may increase inequalities in vaccine uptake within targeted areas, as the intervention was less effective amongst groups that tended to have lower vaccination uptake. Mobile vaccination units should be used in combination with activities to maximise outreach with Black and Asian communities and socioeconomically disadvantaged groups.

Strengths and limitations of this study

- The synthetic control method for microdata offers a rigorous method for identifying control areas that experienced similar levels of COVID-19 vaccine uptake as the intervention areas prior to the introduction of mobile vaccination units, supporting a casual interpretation of the finding of increased uptake in areas with mobile vaccination visits following their introduction.
- The use of individual-level data enabled us to construct weighted Poisson regression models to offer robust estimation of the observed effect, with interaction analysis to reveal whether this effect varied by level of deprivation, age groups and ethnicity.
- We excluded individuals that had used the mobile vaccination units but had not been registered with the GP (general practice) at time of our study, which could lead to the underestimation of the effect.
- As our analysis covers a relatively short follow-up period, we are unable to determine whether the observed effect is due to people being vaccinated earlier than they would otherwise have been or they would have never taken up vaccine without the mobile unit intervention.
- There may also be other differences between places being visited by the mobile vaccination units and those that were not and differences in individual characteristics, beyond those included in this study, that led to the differences in the observed effect.

Introduction

Vaccination is one of the most effective public health interventions for improving health and saving lives.[1] Since the national rollout of the COVID-19 vaccine program on 8th December 2020 in the UK, relatively high uptake of vaccinations has helped reduce the risk of hospitalisation and mortality from COVID-19.[2] Nevertheless, vaccine uptake was lower among young people, socioeconomically disadvantaged groups and ethnic minorities.[3–6] These groups have also often experienced disproportionately greater levels of infections, hospitalisations and deaths during the pandemic. With emerging new SARS-CoV-2 strains like Omicron, additional booster vaccinations are needed to give sufficient protection. Uptake inequalities of these subsequent doses are even greater than first and second doses,[7] potentially undermining responses to new variants that rely largely on increased uptake of booster vaccinations. Currently the UK government is investing £22.5 million to help areas increase uptake amongst ‘hard-to-reach’ groups.[8] A central part of this strategy is to use mobile vaccination units such as pop-up sites and vaccine buses – “taking the vaccines into the hearts of local communities”.[9]

Mobile vaccination units have been used in many countries to increase uptake in disadvantaged communities.[10] These generally involve vaccination clinics based in large vehicles such as buses or temporary pop-up clinics in community settings. As well as bringing vaccines into targeted communities, they usually involve outreach programmes (e.g., leaflet campaigns to advertise vaccination units and explain the benefits of vaccination). The use of mobile vaccination units to increase uptake is based on the premise that geographic accessibility and convenience of vaccination services are potentially important determinants of uptake and that they support uptake from people who have difficulty in accessing existing sites due to information or travel barriers, childcare or healthcare responsibilities, or being excluded from the official healthcare system.[11]

There has been limited research evaluating interventions that aim to increase COVID-19 vaccine uptake. One Randomised Controlled Trial (RCT) shows that provision of information on personal benefit reduces hesitancy,[12] another RCT indicates that text message reminders lead to small increases in uptake.[13] One study of a community-based strategy in an underserved Latinx population in San Francisco found that mobile units reached the intended recipients, but the study was unable to estimate the impact on vaccination uptake.[14] A few studies investigated the impact of interventions aiming to increase Influenza and pneumococcal vaccination, including one systematic review,[15] five RCTs [16–20] and two cluster RCTs.[21,22] Of these, three were published in the United Kingdom,[16,17,21] three in the United States [15,18,19] and two in Hong Kong.[20,22] They

1
2
3 show that sending out reminders, telephone calls and educational outreach tend to increase uptake.
4
5 We found no studies that investigated the impact of mobile vaccination units.
6

7 Mobile vaccination units could be useful to increase uptake in disadvantaged communities, or
8 alternatively largely be used by people who would have attended existing static vaccination clinics,
9 when mobile units had not visited their neighbourhood. It is also unknown if they are effective at
10 increasing uptake amongst socioeconomically disadvantaged and ethnic minority groups. The lack of
11 existing evidence is concerning, considering their central role in current strategies to reduce vaccine
12 uptake inequalities. We therefore used a synthetic control approach to investigate the impact of
13 mobile vaccination units in the Northwest of England and how this varied by age, socioeconomic
14 status, and ethnicity.
15
16
17
18
19
20

21 **Methods**

22 ***Data***

23
24 We utilised anonymised electronic health records (EHR) on all people aged 18 years old and over
25 registered with a General Practice (GP) in Cheshire and Merseyside, England, between 22nd February
26 and 19th July 2021.[23] This data included vaccination status, vaccination date, age, sex, ethnicity,
27 chronic health conditions diagnosed in primary care (chronic obstructive pulmonary disease, chronic
28 heart disease, diabetes, chronic kidney disease asthma, cancer, obesity, depression , and
29 stroke/transient ischaemic attack), whether people were in contact with social care, whether they
30 were a paid carer, travel time to the nearest static vaccination site and the Lower Super Output Areas
31 (LSOA) of residence. LSOAs are small geographical areas of England, with approximately 1500
32 residents each. Ethnicity was based on information of primary care records. Where this is unavailable,
33 ethnicity was taken from hospital, community, or social care records if available in these datasets.
34 Ethnic group was categorised in these datasets using the 17 standard Office for National Statistics
35 Categories. These were then re-coded to 5 categories for analysis (White/White British, Asian/Asian
36 British, Black/Black British, Mixed, and Other).
37
38
39
40
41
42
43
44
45
46
47

48 We linked the EHR data to LSOA-level data, including 2019's indices of multiple deprivation (IMD), an
49 over-crowded housing measure (the proportion of households with at least one-bedroom fewer than
50 they need) based on 2011's Census, and population density using 2019's mid-year population
51 estimates from the Office for National Statistics. The public health teams of the nine local authorities
52 in the Cheshire and Merseyside region were asked to provide a list of locations and dates of mobile
53 vaccination units in their areas between May and November 2021. Six local authorities provided this
54
55
56
57
58
59
60

1
2
3 information and two local authorities reported that they had had no mobile vaccination units. Analysis
4 was therefore limited to these eight local authorities.
5

6 7 **Intervention** 8

9
10 Six local authorities operated mobile vaccination units, that visited 37 sites on 54 occasions, between
11 12th April and 28th June 2021. This included 52 visits from vaccine buses and two from two pop-up
12 clinics. Units were primarily focused on offering first-dose COVID-19 vaccinations to those that had
13 not received a vaccine at any of the city's existing static vaccination sites and were eligible for
14 vaccination at the time.[24] Vaccines were offered on a drop-in basis with no appointment needed.
15 The number of vaccinations received at these mobile units was unavailable for one local authority
16 (Warrington). The total number of first dose vaccinations for the remaining five local authorities was
17 3824. Sites visited by mobile vaccination units were identified by local public health and health service
18 teams based on their knowledge of vaccine uptake, practicalities of having space and permissions to
19 locate the vaccination unit, and relationships with local community groups.
20
21
22
23
24
25

26
27 We defined intervention neighbourhoods as being located within 1km of mobile vaccination sites, and
28 identified 216 LSOAs that were either hosts for mobile vaccination units or had population weighted
29 centroids within a 1km radius of mobile vaccination units. We calculated the start time of the
30 intervention as the week a mobile vaccination unit first visited. This left 1112 non-intervention LSOAs
31 within the eight participating local authorities that had not been visited by mobile vaccination units.
32 We then applied a 'placebo' start time to each of these non-intervention LSOAs, generated uniformly
33 at random in the same weekly proportion as the distribution of intervention start dates for the
34 intervention LSOAs.
35
36
37
38
39

40 41 **Statistical analysis** 42

43
44 We aggregated the individual-level data to construct a panel of weekly measures at the LSOA level
45 from seven weeks (22nd February 2021) before the first mobile vaccination unit visit on 12th April 2021
46 to three weeks (19th July 2021) after the last mobile vaccination unit visit on 28th June 2021. This
47 included LSOA-level measures of total GP registered population size, the proportion of Black/Black
48 British people, the proportion of Asian/Asian British people, the proportion of people of mixed
49 ethnicity, mean age of residents, population density, the proportion of women, the IMD score, the
50 proportion of households living in overcrowded housing, the average travel time to the nearest static
51 vaccine site, the cumulative number of first dose administered at the intervention start time, and the
52 number of new first dose vaccinations administered per week.
53
54
55
56
57
58
59
60

1
2
3 We apply the synthetic control method for microdata developed by Robbins et al. to estimate the
4 effect of mobile vaccination units on vaccine uptake.[25,26] The synthetic control method is a
5 generalisation of difference-in-difference methods.[27] An untreated version of the intervention areas
6 (i.e. a synthetic control) is created using a weighted combination of areas that were unexposed to the
7 intervention. The intervention effect is estimated by comparing the trend in outcomes in the
8 intervention areas to that in the synthetic control areas following the intervention.[28]
9

10
11
12
13
14 The weights are calculated using the raking [29] method so that the weighted averages of all
15 characteristics, for all the variables outlined above in the synthetic control group were the same as for
16 the intervention group. The weighting algorithm derives weights that meet two constraints. Firstly,
17 the sum of first-dose vaccines in the control group equals first-dose vaccines administered in the
18 intervention areas for each of the seven weeks prior to the intervention. Secondly, the weighted
19 average of each local area characteristic, outlined above in the control group equals the average for
20 the intervention areas.[25] Figure A1 in Appendix 1 presents the geographical distribution of these
21 weights and illustrates how the synthetic control group is constructed. The estimated effect of the
22 mobile vaccination unit on the weekly number of first doses, was calculated as the difference between
23 the intervention and the (weighted) synthetic control cohorts in the weekly number of vaccines
24 received over a three-week period after the intervention. Using a weighted regression model to
25 estimate this effect would potentially underestimate standard errors and p-values as this would not
26 account for complex aspects of the process used to generate the synthetic control weights. To
27 estimate the sampling distribution of the treatment effect, and the permuted p-values and 95%
28 confidence intervals, we applied a permutation procedure outlined by Robbins et al. by repeating the
29 analysis through 250 placebo permutations randomly allocating non-intervention LSOAs to the
30 intervention group.[26]
31
32
33
34
35
36
37
38
39
40
41
42

43 As our area-based analysis could be biased by not sufficiently accounting for confounders at the
44 individual level, we additionally conducted analysis using individual-level data on all people aged over
45 18 living in the intervention and non-intervention LSOAs (as defined above), who had been
46 unvaccinated before the mobile vaccination unit first visited their neighbourhood. We used a
47 weighted Poisson regression model, with robust sandwich variance estimators that has been shown
48 to be a valid alternative to the logistic regression model for the analysis of binary outcomes,[30,31] to
49 compare the vaccine rates between these two groups in the three weeks following the intervention.
50 Accounting for systematic area-based differences, we weighted this regression using the synthetic
51 control weights as highlighted above, after additionally controlling for the following individual-level
52 potential confounders: age, sex, ethnicity, health conditions (as described above), whether people
53 were in contact with social care, whether they were paid carers and the travel time by car from each
54
55
56
57
58
59
60

person's address to the nearest static vaccination centre. 18.62% and 0.01% of ethnicity and sex were missing respectively, leaving 233278 records for the main complete case analysis. Appendix 2 presented a sensitivity test removing ethnicity from the main model. We used a Poisson regression model using a sandwich variance estimator to estimate the relative risk of vaccination.[30,31]

To explore whether the mobile vaccination unit effect differed by level of deprivation, ethnicity and age, we fitted another weighted Poisson model including interaction terms between the intervention indicator (mobile vaccination unit) and IMD tercile within Cheshire and Merseyside, ethnic group and age group respectively (see Appendix 3 for detailed results). Additionally, we conducted a sensitivity test by excluding the two pop-up sites from the analysis to check for the robustness of our results (see Appendix 4).

Patient and public involvement

The local authorities delivering the intervention engaged with various community groups in promoting the intervention and identifying intervention sites. Patients and the public were, however, not directly involved in designing this analysis.

Results

Figure 1 shows the intervention (yellow) and the non-intervention areas (purple). The red dots represent the mobile vaccination sites included in our analysis. The map in Appendix 1 shows the weights that were applied to the non-intervention areas to construct the synthetic control.

Figure 1 is about here

Table 1 presents summary statistics for the non-intervention and intervention areas. The average vaccination rate of the first dose was much higher in the non-intervention areas before the introduction of the intervention. On average, residents of the non-intervention areas had to travel slightly longer to get to the nearest static vaccine site. The intervention areas were younger and more deprived, and had a higher proportion of overcrowded households, higher proportions of Asian/Asian British and Black/Black British ethnic minority groups, and higher population density. There were no differences in terms of the proportion of mixed ethnicity. As the matching algorithm achieved an exact match, the *weighted* average of each variable in Table 1 was identical in the synthetic control to those in the intervention areas.

Table 1. The comparison between the intervention and the synthetic control areas at the intervention onset in the 7 weeks prior to the introduction of the mobile vaccination unit.

	Non-intervention areas	Intervention areas
Total population	1495582	338006

% women	51	49
Population density – people per hectare	40	61
Mean age	43	39
% Asian/Asian British	1	3
% Black/Black British	0	2
% Mixed people	1	2
IMD score	29	40
% households with at least one-bedroom fewer than they need	3	4
Average travel time to the nearest stationary vaccine site - minutes	4	3
First dose vaccine uptake among adults prior to intervention (%)	69	53
Average weekly first dose vaccination rate among adults in the 7 weeks prior to intervention (%)	2	2
Number of LSOAs	1112	216

Figure 2 shows the trend in weekly vaccination rate in the intervention and synthetic control areas, during a 11-week period (seven weeks before and three weeks after the introduction of the mobile vaccination unit). For the pre-intervention period, trends were indistinguishable, as the synthetic control algorithm has achieved an exact match by successfully calibrating the weights. From the time point of the intervention being introduced, weekly vaccination rates increased from 1.5% to 1.9% in the intervention areas. Trends in the matched synthetic control areas that were not visited by a mobile vaccination unit remained fairly flat, with a small decrease in the post-intervention period. From two weeks post intervention, 95% CIs stopped overlapping.

Figure 2 is about here

Table 2 shows the estimated effect of the mobile vaccination units on vaccine uptake using two models based on area-level and individual-level data respectively. The two analyses show similar results. The area-based analysis indicates that vaccination rates in the neighbourhoods visited by mobile vaccination units were 23% higher in the three weeks after the first visit, compared to what would have been the case without the mobile vaccination units' visits (RR = 1.23, 95% CI: 1.11 to 1.36). The relative risks adjusted for individual-level characteristics is slightly higher than that of the area-based model (RR = 1.25, 95% CI: 1.21 to 1.28). This overall effect size estimates 3723 additional vaccinations over three weeks of follow-up across the study area, similar to the actual number of people vaccinated in the mobile units (n=3824). This suggests that at least in the short term most of the vaccinations in the mobile units were additional. In other words, among the mobile units' users there were few people, who would have otherwise gone to static centres to get their vaccine. Analysis excluding

ethnicity and the two pop-up sites showed similar results (see Appendix 2 and Appendix 4 respectively).

Table 2. Estimated effect of mobile vaccination units on vaccine uptake, the table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention. Model 1 uses LSOA level data, accounting for area-based differences between intervention and non-intervention areas, with permuted p-values and confidence intervals. Whilst model 2 additionally controls for individual differences between intervention and non-intervention groups.

	RR	95% CI		p-value
		LCL	UCL	
Model 1. LSOA level synthetic control analysis	1.23	1.11	1.36	<0.001
Model 2. Individual level weighted Poisson regression analysis	1.25	1.21	1.28	<0.001

Note: RR is relative risk. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

Interaction analyses investigated effective modification by deprivation, ethnicity and age (see Table A2 in Appendix 3). We found lower impact of the mobile vaccination unit on the vaccination rate for the most deprived areas ($p<0.001$) compared to more affluent areas, a lower impact for Asian/Asian British ($p=0.006$), Black/Black British ($p=0.005$) or other ethnic groups ($p=0.010$), compared to White/White British people, and a lower impact on vaccine uptake for people aged 31-65 compared to 18-30 year olds ($p<0.001$).

Figure 3 is about here

Figure 3 shows the estimated impact of the mobile vaccination units for all the subgroups based on the linear combination of parameters from the regression model including interaction terms for deprivation, ethnicity and age group (Figure 3). Due to the small sample sizes within each of these 45 subgroups, these results should be treated with caution. However, they indicate the likely pattern of effects of the intervention across these groups. Overall, White, 18-30 age group living in neighbourhoods of intermediated deprivation appeared to benefit the most from visits of the mobile vaccination unit (Figure 3). Effects were lowest for older age groups in the most deprived areas. Although the effect of the mobile vaccination unit may be lower for the most deprived population and for people from Black, Asian and other ethnic minority groups, the mobile vaccination unit does still appear to have increased uptake in these groups, particularly for younger people.

Discussion

Our study presents much-needed empirical evidence of the effectiveness of mobile vaccination units in promoting COVID-19 vaccination, indicating that they can increase uptake in their targeted neighbourhoods. Within those neighbourhoods, however, the intervention tended to increase uptake most amongst younger people, white people and less socioeconomically deprived areas. However, the targeted neighbourhoods were mostly highly deprived. Our analysis indicated that the intervention was similarly effective in the least deprived and intermediate levels of deprivation *within* these targeted neighbourhoods. It is only in areas with IMD score of over 53, the lower bound of the most deprived, that the effectiveness declined. However, 53 is at the 95th percentile of the national distribution of IMD scores, representing very deprived areas nationwide. Our findings indicate therefore that the intervention was effective at increasing uptake amongst young people in relatively deprived areas (although not in extremely deprived areas) and across young people from all ethnic groups in these areas.

Our study has limitations. We only had data on individuals who had been registered with the GP at time of our study. Although unregistered people attending for mobile units were encouraged and can register with a GP at their appointment, there may have been people vaccinated who did not wish to be registered, such as undocumented immigrants, homeless populations, travellers, and displaced people. We were unable to estimate the impact of the intervention in these groups. The mobile vaccination unit could have increased uptake due to improved accessibility through the mobile vaccination unit itself and/or the awareness raising and publicity associated with visits of these units. Unfortunately, in our analysis we are unable to distinguish between these effects.

Our analysis covers a relatively short period of follow-up. We are therefore unable to determine whether the observed effect is due to people being vaccinated earlier than they would otherwise have been or if they would have never taken up vaccine without the intervention. Although we have accounted for observed differences between places visited by the mobile vaccination units and those not and differences in individual characteristics, it is still possible that unmeasured confounding could bias the results.

Conclusion

Our study has implications for strategies aiming to increase vaccine uptake. By improving geographic accessibility of the COVID-19 vaccine, the mobile vaccination unit shows promise for improving vaccine uptake of the first dose. The evidence indicating greater effects in less deprived areas and in the White/White British population raises concerns that the intervention could however lead to an increase in inequalities in uptake within targeted areas. It is important to ensure the mobile

1
2
3 vaccination units are effectively targeted to the communities with low uptake and combined with
4 comprehensive engagement and outreach with Black and Asian ethnic groups and with more
5 socioeconomically disadvantaged communities. With emerging new variants and the need for
6 multiple doses to achieve sufficient immunity, rapidly increasing uptake and reducing inequalities in
7 uptake has become of critical public health importance. Deployment of mobile units alongside other
8 effective approaches to increase uptake in disadvantaged groups can contribute to this goal.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Transparency statement

The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

Author contribution statement

B.B. conceived the original idea, devised the project, the main conceptual ideas and proof outline. X.Z. contributed to the literature review, collected the data, and carried out the data analysis. R.A. conducted the initial literature review. X.Z. drafted the manuscript and designed the figures with support from B.B. and M.G.. J.T., S.K. and P.P. assisted with the data access and commented on the manuscript. R.P. assisted in coding. M.GF and M.G. aided in commenting on the manuscript. I.B. aided in supervising the project and commented on the manuscript. S.B. helped to improve the language and visualisation. All authors provided critical feedback and helped to shape the research manuscript.

Conflicts of interest statement

We have no conflicts of interest to disclose.

Ethics statements

Patient consent for publication

Not required.

Ethics approval

University Research Ethics Committee review is not required by the University of Liverpool for the secondary analysis of data which have been anonymised by an external party and are provided to the research team in a fully anonymised format.

Data sharing statement

The individual-level data is sensitive and could not be shared. But statistical codes are available from the corresponding author upon request.

Funding

This research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections (ref NIHR200910), the NIHR Policy Research Programme (RESTORE; Award ID, NIHR202484) and the NIHR Applied Research Collaboration Northwest Coast (NWC ARC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care or Public Health England.

References

- 1 WHO | Vaccination greatly reduces disease, disability, death and inequity worldwide. WHO. <https://www.who.int/bulletin/volumes/86/2/07-040089/en/> (accessed 3 Jun 2021).
- 2 Baraniuk C. Covid-19: How the UK vaccine rollout delivered success, so far. *BMJ* 2021;**372**:n421. doi:10.1136/bmj.n421
- 3 Campos-Matos I, Mandal S, Yates J, *et al.* Maximising benefit, reducing inequalities and ensuring deliverability: Prioritisation of COVID-19 vaccination in the UK. *Lancet Reg Health-Eur* 2021;**2**.
- 4 Razai MS, Osama T, McKechnie DG, *et al.* Covid-19 vaccine hesitancy among ethnic minority groups. British Medical Journal Publishing Group 2021.
- 5 Osama T, Razai MS, Majeed A. COVID-19 vaccine allocation: addressing the United Kingdom's colour-blind strategy. *J R Soc Med* 2021;:01410768211001581.
- 6 Collaborative TO, MacKenna B, Curtis HJ, *et al.* Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY. *medRxiv* 2021;:2021.01.25.21250356. doi:10.1101/2021.01.25.21250356
- 7 Vaccine Coverage - Third/Booster Doses | OpenSAFELY: Reports. <http://reports.opensafely.org/reports/vaccine-coverage-thirdbooster-doses/> (accessed 21 Dec 2021).
- 8 £22.5m of funding announced in new community push to get nation boosted now. GOV.UK. <https://www.gov.uk/government/news/225m-of-funding-announced-in-new-community-push-to-get-nation-boosted-now> (accessed 20 Dec 2021).
- 9 Final report on progress to address COVID-19 health inequalities. GOV.UK. <https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-health-inequalities/final-report-on-progress-to-address-covid-19-health-inequalities> (accessed 21 Dec 2021).
- 10 ECDC. Facilitating vaccination acceptance and uptake in the EU/EEA. Stockholm: : ECDC 2021. <https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-acceptance-and-uptake>
- 11 Armocida B, Formenti B, Missoni E, *et al.* Challenges in the equitable access to COVID-19 vaccines for migrant populations in Europe. *Lancet Reg Health – Eur* 2021;**6**. doi:10.1016/j.lanepe.2021.100147
- 12 Freeman D, Loe BS, Yu L-M, *et al.* Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial. *Lancet Public Health* 2021;**0**. doi:10.1016/S2468-2667(21)00096-7
- 13 Dai H, Saccardo S, Han MA, *et al.* Behavioural nudges increase COVID-19 vaccinations. *Nature* 2021;**597**:404–9. doi:10.1038/s41586-021-03843-2
- 14 Marquez C, Kerkhoff AD, Naso J, *et al.* A multi-component, community-based strategy to facilitate COVID-19 vaccine uptake among Latinx populations: From theory to practice. *PLOS ONE* 2021;**16**:e0257111. doi:10.1371/journal.pone.0257111

- 15 Ecartot F, Maggi S, Michel J-P. Strategies to improve vaccine uptake throughout adulthood. *Vaccines Older Adults Curr Pract Future Oppor* 2020;**43**:234–48.
- 16 Arthur AJ, Matthews RJ, Jagger C, *et al.* Improving uptake of influenza vaccination among older people: a randomised controlled trial. *Br J Gen Pract* 2002;**52**:717–22.
- 17 Hull S, Hagdrup N, Hart B, *et al.* Boosting uptake of influenza immunisation: a randomised controlled trial of telephone appointing in general practice. *Br J Gen Pract* 2002;**52**:712–6.
- 18 Humiston SG, Bennett NM, Long C, *et al.* Increasing inner-city adult influenza vaccination rates: a randomized controlled trial. *Public Health Rep* 2011;**126**:39–47.
- 19 Krieger JW, Castorina JS, Walls ML, *et al.* Increasing influenza and pneumococcal immunization rates: a randomized controlled study of a senior center–based intervention. *Am J Prev Med* 2000;**18**:123–31.
- 20 Leung KC, Mui C, Chiu WY, *et al.* Impact of patient education on influenza vaccine uptake among community-dwelling elderly: a randomized controlled trial. *Health Educ Res* 2017;**32**:455–64.
- 21 Siriwardena AN, Rashid A, Johnson MR, *et al.* Cluster randomised controlled trial of an educational outreach visit to improve influenza and pneumococcal immunisation rates in primary care. *Br J Gen Pract* 2002;**52**:735–40.
- 22 Chan SS, Leung DY, Leung AY, *et al.* A nurse-delivered brief health education intervention to improve pneumococcal vaccination rate among older patients with chronic diseases: a cluster randomized controlled trial. *Int J Nurs Stud* 2015;**52**:317–24.
- 23 CIPHA -. <https://www.cipha.nhs.uk/> (accessed 21 Dec 2021).
- 24 Best J. How the JCVI sets who gets a covid-19 vaccine and when. *BMJ* 2021;**373**:n820. doi:10.1136/bmj.n820
- 25 Robbins MW, Davenport S. microsynth: Synthetic Control Methods for Disaggregated and Micro-Level Data in R. *J Stat Softw Vol 1 Issue 2 2021* Published Online First: 14 January 2021. <https://www.jstatsoft.org/v097/i02>
- 26 Robbins MW, Saunders J, Kilmer B. A Framework for Synthetic Control Methods With High-Dimensional, Micro-Level Data: Evaluating a Neighborhood-Specific Crime Intervention. *J Am Stat Assoc* 2017;**112**:109–26. doi:10/f9746k
- 27 Barr B, Zhang X, Green M, *et al.* A blueprint for synthetic control methodology: a causal inference tool for evaluating natural experiments in population health. *bmj* 2022;**379**.
- 28 Zhang X, Owen G, Green M, *et al.* Evaluating the Impacts of Tiered Restrictions Introduced in England, During October and December 2020 on COVID-19 Cases: A Synthetic Control Study. Rochester, NY: : Social Science Research Network 2021. doi:10.2139/ssrn.3805859
- 29 Raking. In: *Encyclopedia of Survey Research Methods*. 2455 Teller Road, Thousand Oaks California 91320 United States of America: : Sage Publications, Inc. 2008. doi:10.4135/9781412963947.n433
- 30 Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. *Am J Epidemiol* 2004;**159**:702–6. doi:10.1093/aje/kwh090

- 1
2
3 31 Greenland S. Model-based estimation of relative risks and other epidemiologic measures in
4 studies of common outcomes and in case-control studies. *Am J Epidemiol* 2004;**160**:301–5.
5 doi:10.1093/aje/kwh221
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3 **Figure 1. Location of eligible mobile vaccination units (red dots) and the non-intervention (purple)**
4 **and intervention (yellow) areas across Cheshire and Merseyside. The sub-map in the box of the**
5 **top right shows the location of Cheshire and Merseyside in England.**
6
7
8

9 **Figure 2. The trend in the weekly vaccination rate with their 95% confidence intervals in the**
10 **intervention and synthetic control areas.**
11
12
13

14 **Figure 3. Heatmap of the estimated impact of the mobile vaccination units for all the subgroups**
15 **based on interaction analysis.**
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




406x355mm (600 x 600 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



2257x1975mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




2257x1975mm (72 x 72 DPI)

1
2
3 **Appendices**

4
5 **Appendix 1. Geographical pattern of weights in area-based synthetic control analysis.**

6
7 **Figure A1. Weighting of areas outside of the catchment of the mobile vaccination unit to construct the synthetic control group. Areas within the catchment of the mobile vaccination unit are coloured black, whilst locations of the mobile vaccination unit are represented by red dots. The white non-intervention areas are those that have been allocated zero weights in constructing the synthetic control.**



51 **Appendix 2. Sensitivity test – excluding ethnicity from the main model**

52 **Table A1. Results of analysis for adult individuals of all ages, excluding ethnicity.**

53
54
55
56
57
58
59
60

	RR	95% CI		p-value
		LCL	UCL	
Model 2. Individual level weighted Poisson regression analysis	1.24	1.21	1.28	<0.001

Results of Table A1 and Table 2 are almost identical, implying that excluding cases with missing information on ethnicity did not affect the robustness of our results.

Appendix 3. Regression output for the interaction model based on adult individuals.

Table A2. Regression output for the interaction model based on adult individuals. The table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention.

Variables	RR	95% CI		p-value
		LCL	UCL	
Mobile vaccination unit	1.68	1.58	1.79	<0.001
Age group (reference: 18-30 years old)				
(30,65]	1.25	1.19	1.31	<0.001
65+	0.20	0.15	0.28	<0.001
Sex (reference: Women)				
Men	1.01	0.98	1.04	0.400
Ethnicity (reference: White/White British)				
Asian/Asian British	0.92	0.79	1.07	0.300
Black/Black British	0.75	0.60	0.93	0.008
Mixed	0.75	0.61	0.91	0.005
Other ethnic groups	0.80	0.75	0.86	<0.001
IMD tercile (reference: Least deprived)				
Intermediate deprivation	0.79	0.74	0.83	<0.001
Most deprived areas	0.67	0.63	0.72	<0.001
Chronic health conditions	1.10	1.08	1.12	<0.001
Carer	0.32	0.27	0.37	<0.001
Social care receiver	0.98	0.76	1.25	0.900
Travel time to the nearest static vaccine centre (minutes)	1.09	1.08	1.09	<0.001
Interaction between age groups and mobile vaccination unit (reference: 18-30 years old with mobile vaccination unit)				
30-65 years old with mobile vaccination unit	0.64	0.60	0.68	<0.001
65+ years old with mobile vaccination unit	0.70	0.48	1.03	0.070
Interaction between ethnicity and mobile vaccination unit (reference: White/White British with mobile vaccination unit)				
Asian/Asian British with mobile vaccination unit	0.79	0.66	0.94	0.006
Black/Black British with mobile vaccination unit	0.70	0.55	0.90	0.005
Mixed with mobile vaccination unit	0.90	0.71	1.14	0.400
Other ethnic groups with mobile vaccination unit	0.90	0.84	0.98	0.010
Interaction between IMD tercile and mobile vaccination unit (reference: Least deprived with mobile vaccination unit)				
Intermediate deprivation with mobile vaccination unit	1.08	1.01	1.16	0.024
Most deprived areas with mobile vaccination unit	0.77	0.72	0.83	<0.001
Note: The intercept is excluded from the output.				

1
2
3 **Appendix 4. Sensitivity test – excluding the two pop-up sites across C&M**
4

5 **Table A3. Results of analysis for adult individuals of all ages, excluding the two pop-up sites.**
6

7
8
9
10
11
12
13

	RR	95% CI		p-value
		LCL	UCL	
Model 2. Individual level weighted Poisson regression analysis	1.23	1.18	1.29	<0.001

14
15 Table A3 shows very similar results to those of Table 2, indicating that it is unlikely that the use of pop-
16 up sites rather than vaccine bus type approaches influenced our results.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

Reporting Item		Page Number
Title and abstract		1-2
Title	#1a Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b Provide in the abstract an informative and balanced summary	2

of what was done and what was found

Introduction

4-5

Background /
rationale

[#2](#)

Explain the scientific background and rationale for the investigation being reported

4-5

Objectives

[#3](#)

State specific objectives, including any prespecified hypotheses

5

Methods

5-8

Study design

[#4](#)

Present key elements of study design early in the paper

5-8

Setting

[#5](#)

Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection

5-6

Eligibility criteria

[#6a](#)

Give the eligibility criteria, and the sources and methods of selection of participants.

5-6

[#7](#)

Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable

6-8

Data sources /
measurement

[#8](#)

For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for exposed and unexposed groups if applicable.

5-6

Bias

[#9](#)

Describe any efforts to address potential sources of bias

7-8

Study size

[#10](#)

Explain how the study size was arrived at

7-8

1	Quantitative	#11	Explain how quantitative variables were handled in the	5-6
2				
3	variables		analyses. If applicable, describe which groupings were chosen,	
4				
5			and why	
6				
7				
8				
9	Statistical	#12a	Describe all statistical methods, including those used to control	6-8
10				
11	methods		for confounding	
12				
13				
14	Statistical	#12b	Describe any methods used to examine subgroups and	8
15				
16	methods		interactions	
17				
18				
19	Statistical	#12c	Explain how missing data were addressed	7-8
20				
21	methods			
22				
23				
24				
25	Statistical	#12d	If applicable, describe analytical methods taking account of	
26				
27	methods		sampling strategy	
28				
29				
30	Statistical	#12e	Describe any sensitivity analyses	7-8
31				
32	methods			
33				
34				
35	Results			8-10
36				
37				
38				
39	Participants	#13a	Report numbers of individuals at each stage of study—eg	
40				
41			numbers potentially eligible, examined for eligibility, confirmed	
42				
43			eligible, included in the study, completing follow-up, and	
44				
45			analysed. Give information separately for for exposed and	
46				
47			unexposed groups if applicable.	
48				
49				
50				
51	Participants	#13b	Give reasons for non-participation at each stage	
52				
53				
54	Participants	#13c	Consider use of a flow diagram	
55				
56				
57	Descriptive data	#14a	Give characteristics of study participants (eg demographic,	8-9
58				
59				
60				

clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.

1			
2			
3			
4			
5			
6			
7			
8	Descriptive data	#14b	Indicate number of participants with missing data for each
9			variable of interest
10			
11			
12			
13	Outcome data	#15	Report numbers of outcome events or summary measures. 9
14			
15			
16			Give information separately for exposed and unexposed
17			groups if applicable.
18			
19			
20			
21	Main results	#16a	Give unadjusted estimates and, if applicable, confounder- 9-10
22			
23			adjusted estimates and their precision (eg, 95% confidence
24			interval). Make clear which confounders were adjusted for and
25			why they were included
26			
27			
28			
29			
30			
31	Main results	#16b	Report category boundaries when continuous variables were
32			categorized
33			
34			
35			
36	Main results	#16c	If relevant, consider translating estimates of relative risk into 10
37			
38			absolute risk for a meaningful time period
39			
40			
41			
42	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups and 10
43			
44			interactions, and sensitivity analyses
45			
46			
47	Discussion		10-12
48			
49			
50	Key results	#18	Summarise key results with reference to study objectives 10-11
51			
52			
53	Limitations	#19	Discuss limitations of the study, taking into account sources of 11
54			
55			potential bias or imprecision. Discuss both direction and
56			magnitude of any potential bias.
57			
58			
59			
60			

1 Interpretation [#20](#) Give a cautious overall interpretation considering objectives, 11-12
2
3
4 limitations, multiplicity of analyses, results from similar studies,
5
6 and other relevant evidence.
7

8
9 Generalisability [#21](#) Discuss the generalisability (external validity) of the study 11-12
10
11 results
12
13

14 Other Information

15
16
17 Funding [#22](#) Give the source of funding and the role of the funders for the 13
18
19 present study and, if applicable, for the original study on which
20
21 the present article is based
22
23
24

25 None The STROBE checklist is distributed under the terms of the Creative Commons Attribution
26
27 License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool
28
29 made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Evaluating the impact of using mobile vaccination units to increase COVID-19 vaccination uptake in Cheshire and Merseyside, UK: A synthetic control analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071852.R1
Article Type:	Original research
Date Submitted by the Author:	07-Aug-2023
Complete List of Authors:	Zhang, Xingna; University of Liverpool, Department of Public Health, Policy & Systems Tulloch, John; University of Liverpool, HPRU EZI Knott, Shane; Liverpool Liverpool City Council Allison, Rachel; Russells Hall Hospital Parvulescu, Paula; Liverpool City Council Buchan, Iain; University of Liverpool, Public Health and Policy Garcia-Finana, Marta; University of Liverpool, Department of Health Data Science; Clinical Trials Research Centre, Piroddi, Roberta; University of Liverpool, Department of Public Health, Policy & Systems Green, Mark; University of Liverpool, Geography & Planning Baird, Sophie; The UK Health Security Agency Barr, Ben ; University of Liverpool, Department Public Health and Policy
Primary Subject Heading:	Public health
Secondary Subject Heading:	Infectious diseases, Health policy
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **1 Evaluating the impact of using mobile vaccination units to increase COVID-19 vaccination**
4 **2 uptake in Cheshire and Merseyside, UK: A synthetic control analysis.**

5
6 3 Xingna Zhang¹, John Tulloch², Shane Knott³, Rachel Allison⁴, Paula Parvulescu⁵, Iain Buchan⁶, Marta
7 4 García-Fiñana⁷, Roberta Piroddi⁸, Mark A. Green⁹, Sophie Baird¹⁰, Ben Barr¹¹

8
9 5 ¹ Tenure Track Fellow, Department of Public Health, Policy & Systems, University of Liverpool,
10 6 Liverpool, UK

11
12 7 ² Tenure Track Fellow, Department of Livestock and One Health in the Institute of Infection,
13 8 Veterinary and Ecological Science, University of Liverpool, Liverpool, UK

14
15 9 ³ Senior Public Health Practitioner (Healthcare), Liverpool City Council, Liverpool, UK

16
17 10 ⁴ FY1 Doctor, Russells Hall Hospital, Dudley, UK

18
19 11 ⁵ Consultant in Public Health Medicine, Liverpool City Council, Liverpool, UK

20
21 12 ⁶ Chair in Public Health and Clinical Informatics, Department of Public Health, Policy & Systems,
22 13 University of Liverpool, Liverpool, UK

23
24 14 ⁷ Professor of Health Data Science, Department of Health Data Science, University of Liverpool,
25 15 Liverpool, UK

26
27 16 ⁸ Research Fellow, Department of Public Health, Policy & Systems, University of Liverpool, Liverpool,
28 17 UK

29
30 18 ⁹ Reader in Health Geography, Department of Geography & Planning, University of Liverpool,
31 19 Liverpool, UK

32
33 20 ¹⁰ Public Health Registrar, The UK Health Security Agency, UK

34
35 21 ¹¹ Chair in Applied Public Health Research, Department of Public Health, Policy & Systems, University
36 22 of Liverpool, Liverpool, UK

37
38
39
40
41
42 25 Corresponding author:

43
44 26 Xingna Zhang

45
46 27 xingna.zhang@liverpool.ac.uk

47
48 28 WORD COUNT (excluding title page, abstract, figures, tables, references, author statements and
49 29 appendices): 4118

50
51 30 No of Tables (excluding Appendix): 2

52
53 31 No of Figures (excluding Appendix): 3

54
55 32 Supplementary files: 12 appendices at the end of this document

56
57 33

1
2
3 1 **ABSTRACT**
4

5 2 **Objective** To evaluate the impact of mobile vaccination units on COVID-19 vaccine uptake of the first
6
7 3 dose, the percentage of vaccinated people among the total eligible population. We further
8
9 4 investigate whether such an effect differed by deprivation, ethnicity, and age.

10
11 5 **Design** Synthetic control analysis.
12

13 6 **Setting** The population registered with General Practices (GPs) in nine local authority areas in
14
15 7 Cheshire and Merseyside in Northwest England, UK.
16

17 8 **Intervention** Mobile vaccination units that visited 37 sites on 54 occasions between 12th April and
18
19 9 28th June 2021. We defined populations as having received the intervention if they lived within 1km
20
21 10 of a mobile vaccination site (338,006 individuals). A weighted combination of neighbourhoods that
22
23 11 had not received the intervention (1,495,582 individuals) was used to construct a synthetic control
24
25 12 group.
26

27 13 **Outcome** The weekly number of first-dose vaccines received among people aged 18 years and over
28
29 14 as a proportion of the population.
30

31 15 **Results** The introduction of a mobile vaccination unit into a neighbourhood increased the number of
32
33 16 first vaccinations conducted in the neighbourhood by 25% (95% CI: 21% to 28%) within three weeks
34
35 17 after the first visit to a neighbourhood, compared to the synthetic control group. This effect was
36
37 18 smaller amongst 30–65-year-olds compared to 18–30-year-olds, amongst Asian and Black ethnic
38
39 19 groups compared to White ethnic groups, and the most socioeconomically deprived populations
40
41 20 compared to the least deprived areas.

42 21 **Conclusions** Mobile vaccination units are effective interventions for increasing vaccination uptake, at
43
44 22 least in the short-term. While mobile units can be geographically targeted to reduce inequalities, we
45
46 23 found evidence that they may increase inequalities in vaccine uptake within targeted areas, as the
47
48 24 intervention was less effective amongst groups that tended to have lower vaccination uptake.
49
50 25 Mobile vaccination units should be used in combination with activities to maximise outreach with
51
52 26 Black and Asian communities and socioeconomically disadvantaged groups.
53
54 27
55 28
56
57
58
59
60

1 **Strengths and limitations of this study**

- 2 - The synthetic control method for microdata offers a rigorous method for identifying control
3 areas that experienced similar levels of COVID-19 vaccine uptake as the intervention areas
4 prior to the introduction of mobile vaccination units, supporting a possible causal
5 interpretation of the finding of increased uptake in areas with mobile vaccination visits
6 following their introduction.
- 7 - The use of individual-level data enabled us to construct weighted Poisson regression models
8 to offer robust estimation of the observed effect, with interaction analysis to reveal whether
9 this effect varied by level of deprivation, age groups and ethnicity.
- 10 - We were not able to include individuals that had used the mobile vaccination units but had
11 not been registered with the GP at time of our study, which could lead to the underestimation
12 of the effect given that the main vaccination programme was provided through GPs.
- 13 - As our analysis covers a relatively short follow-up period, the results may not reflect the
14 sustained impact of the intervention over longer periods of time.
- 15 - There may also be other differences between places being visited by the mobile vaccination
16 units and those that were not and differences in individual characteristics, beyond those
17 included in this study, that led to the differences in the observed effect.

1 Introduction

Vaccination is one of the most effective public health interventions for improving health and saving lives.[1] Following the national rollout of the COVID-19 vaccine program on 8th December 2020 in the UK, relatively high vaccine uptake has helped reduce the risk of hospitalisation and mortality from COVID-19.[2] Nevertheless, vaccine uptake was lower among young people, socioeconomically disadvantaged groups and ethnic minorities for a combination of factors including vaccine eligibility (Appendix 1 presents the timeline for age eligibility of the first dose of the COVID-19 vaccine in England) and hesitancy, health disparities and inequalities, convenience and access, language and cultural barriers, and trust in healthcare systems.[3–6] Some of these groups have also often experienced disproportionately greater levels of infections, hospitalisations and deaths during the pandemic. With successive SARS-CoV-2 variants, additional booster vaccinations were needed to give sufficient protection. Inequalities in uptake of these subsequent doses were greater than with the initial doses,[7] potentially undermining responses to new variants that rely largely on increased uptake of booster vaccinations. The UK government invested £22.5 million to help areas increase uptake amongst hard-to-reach groups in December 2021, as tackling health inequalities is a core government priority.[8] A central part of this strategy was to use mobile vaccination units such as pop-up sites and vaccine buses – “taking the vaccines into the hearts of local communities”.[9]

Mobile vaccination units have been used in many countries to increase uptake in disadvantaged communities.[10] These generally involve vaccination clinics based in large vehicles such as buses or temporary pop-up clinics in community settings. As well as bringing vaccines into targeted communities, they usually involve outreach programmes (e.g., leaflet campaigns to advertise vaccination units and explain the benefits of vaccination). The use of mobile vaccination units to increase uptake is based on the premise that geographic accessibility and convenience of vaccination services are potentially important determinants of uptake and that they support uptake from people who have difficulty in accessing existing sites due to information or travel barriers, childcare or healthcare responsibilities, or being excluded from the official healthcare system.[11]

Although former studies found mobile units as useful tools to reduce health inequalities in administering other forms of preventative care such as cancer screening,[12–15] there has been limited research evaluating interventions that aim to increase COVID-19 vaccine uptake. One Randomised Controlled Trial (RCT) shows that provision of information on personal benefit reduces hesitancy,[16] with another RCT indicating that text message reminders lead to small increases in uptake.[17] One study of a community-based strategy in an underserved Latinx population in San Francisco found that mobile units reached their intended recipients, but the study was unable to

1
2
3 1 estimate the impact on vaccination uptake.[18] Another study found that users of the COVID-19
4 2 mobile vaccination units tended to be younger, non-White race, and Hispanic ethnicity compared to
5 3 the general vaccinated populations in the Greater Boston area, suggesting the potential benefits of
6 4 mobile vaccination units without estimating the average treatment effect.[19] A few studies
7 5 investigated the impact of interventions aiming to increase Influenza and pneumococcal vaccination,
8 6 including one systematic review,[20] five RCTs [21–25] and two cluster RCTs.[26,27] Of these, three
9 7 were published in the United Kingdom,[21,22,26] three in the United States [20,23,24] and two in
10 8 Hong Kong.[25,27] They all show that sending out reminders, telephone calls and educational
11 9 outreach tend to increase uptake. We found no studies that quantified the effect of introducing
12 10 mobile vaccination units on COVID-19 vaccine uptake.

13 11 It also remains largely uncertain how effective mobile vaccination units are at increasing uptake
14 12 amongst disadvantaged groups, having been deployed to improve vaccine access for those
15 13 communities.[2,18,19] The lack of existing evidence is concerning, considering their central role in the
16 14 strategies to reduce vaccine uptake inequalities. We therefore used a synthetic control approach to
17 15 investigate the impact of mobile vaccination units in the Northwest of England and how this varied by
18 16 age, socioeconomic status, and ethnicity.

17 **Methods**

18 ***Data***

19 We utilised anonymised electronic health records (EHR) on all people aged 18 and over, registered
20 with a General Practice (GP) in Cheshire and Merseyside, England, between 22nd February and 19th
21 July 2021.[28] This data included vaccination status, vaccination date, age, sex, ethnicity, chronic
22 health conditions diagnosed in primary care (chronic obstructive pulmonary disease, chronic heart
23 disease, diabetes, chronic kidney disease asthma, cancer, obesity, depression, and stroke/transient
24 ischaemic attack), whether people were in contact with social care, whether they were a paid carer,
25 travel time by car to the nearest conventional static vaccination site requiring booking in advance and
26 the Lower Super Output Areas (LSOA) of residence. LSOAs are small geographical areas of England,
27 with approximately 1500 residents each. Ethnicity was based on information of primary care records.
28 Where unavailable, ethnicity was taken from hospital, community, or social care records if available
29 in these datasets. Ethnicity was categorised in these datasets using the 17 standard Office for National
30 Statistics Categories. These were then re-coded to 5 categories for analysis (White/White British,
31 Asian/Asian British, Black/Black British, Mixed, and Other).

1
2
3 1 We linked the EHR data to LSOA-level data, including 2019's indices of multiple deprivation (IMD) – a
4 2 composite measure of deprivation across seven domains (income, employment, education, health,
5 3 crime, barriers to housing & services, and living environment), an over-crowded housing measure (the
6 4 proportion of households with at least one-bedroom fewer than they need) based on 2011's Census,
7 5 and population density using 2019's mid-year population estimates from the Office for National
8 6 Statistics. The public health teams of the nine local authorities in the Cheshire and Merseyside region
9 7 were asked to provide a list of locations and dates of mobile vaccination units in their areas between
10 8 May and November 2021. Six local authorities provided this information and two local authorities
11 9 reported that they had had no mobile vaccination units. Analysis was therefore limited to these eight
12 10 local authorities.

11 ***Intervention***

12 Six local authorities operated mobile vaccination units, that visited 37 sites on 54 occasions, between
13 12th April and 28th June 2021. This included 52 visits from vaccine buses and two from two pop-up
14 14 static clinics (different from conventional static vaccination sites, these two pop-up sites offered walk-
15 15 in services without the need to book in advance). Six sites were visited more than once during our
16 16 study period, with repeated visits scheduled either consecutively or at least one week apart. Vaccines
17 17 were offered typically from 9am to 4.30pm or 5pm on the day of most visits, with four visits operating
18 18 from 8am to 6pm, 9am to 3pm, 9.15am to 2.30pm and 10am to 2pm respectively. We chose to treat
19 19 all sites uniformly in our analysis to avoid potentially overemphasising the impact of sites with multiple
20 20 visits and minimise the potential influence of site-specific factors. This simplifying assumption offers
21 21 us a more conservative approach and allows us to focus on the overall effect of the intervention rather
22 22 than site-specific variations, thus enabling clearer interpretation and generalisability of the results.
23 23 The deployment of the mobile vaccination units also involved outreach programmes to advertise
24 24 vaccination units and explain the benefits of vaccination for each visit. Units were primarily focused
25 25 on offering first-dose COVID-19 vaccinations to those that had not received a vaccine at any of the
26 26 city's existing conventional static vaccination sites and were eligible for vaccination at the time.[29]
27 27 Vaccines were offered on a drop-in basis with no appointment needed. The number of vaccinations
28 28 received at these mobile units was unavailable for one local authority (Warrington). The total number
29 29 of first dose vaccinations for the remaining five local authorities that had deployed the mobile
30 30 vaccination units was 3824. Sites visited by mobile vaccination units were identified by local public
31 31 health and health service teams based on their knowledge of vaccine uptake (i.e., the percentage of
32 32 adults who have received the first dose of the COVID-19 vaccine among the total eligible adult
33 33 population in our study), practicalities of having space and permissions to locate the vaccination unit,
34 34 and relationships with local community groups.

1
2
3 1 We defined intervention neighbourhoods as being located within 1km of mobile vaccination sites and
4 identified 216 LSOAs that were either hosts for mobile vaccination units or had population weighted
5 2 centroids within a 1km radius of mobile vaccination units. We calculated the start time of the
6 3 intervention as the week a mobile vaccination unit first visited. This left 1112 non-intervention LSOAs
7 4 within the eight participating local authorities that had not been visited by mobile vaccination units.
8 5 We then applied a 'placebo' start time to each of these non-intervention LSOAs, generated uniformly
9 6 at random in the same weekly proportion as the distribution of intervention start dates for the
10 7 intervention LSOAs.
11 8

9 ***Statistical analysis***

10 We aggregated the individual-level data to construct a panel of weekly measures at the LSOA level
11 from seven weeks (22nd February 2021) before the first mobile vaccination unit visit on 12th April 2021
12 to three weeks (19th July 2021) after the last mobile vaccination unit visit on 28th June 2021. We chose
13 seven weeks as our pre-intervention period after evaluating trends of the accumulated uptake, overall
14 and by ethnic and socio-economic groups, with consideration of the rollout of the vaccine prioritised
15 by age groups (Appendix 1 and 2). A seven-week pre-intervention period allowed us to capture trends
16 for most people eligible for the vaccine and focus on the intervention at a relatively stable stage of
17 the pandemic. We then chose a three-week follow-up period due to the policy change in July 2021 to
18 prioritise administering the second doses. A three-week period avoided spill-over effect of this
19 prioritisation and allowed us to estimate the effect of repeated visits in some sites and the
20 accompanying outreach programmes. We therefore aimed to investigate the short-term effect of the
21 intervention here. The weekly panel data included LSOA-level measures of total GP registered
22 population size, the proportion of Black/Black British people, the proportion of Asian/Asian British
23 people, the proportion of people of mixed ethnicity, mean age of residents, population density, the
24 proportion of women, the IMD score, the proportion of households living in overcrowded housing,
25 the average travel time by car to the nearest conventional static vaccine site, the cumulative number
26 of first dose administered at the start of the pre-intervention period, and the number of new first dose
27 vaccinations administered per week (Appendix 3 compares these measures between the intervention
28 and the rest of Cheshire and Merseyside).

29 We apply the synthetic control method for microdata developed by Robbins et al. to estimate the
30 effect of mobile vaccination units on vaccine uptake. Our outcome variable, weekly vaccine uptake, is
31 the percentage of adults who have received the first dose of the COVID-19 vaccine during each week
32 among the total eligible adult population.[30,31] The synthetic control method is a generalisation of
33 difference-in-difference methods.[32] An untreated version of the intervention areas (i.e. a synthetic
34

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

control) is created using a weighted combination of areas that were unexposed to the intervention. The intervention effect is estimated by comparing the trend in outcomes in the intervention areas to that in the synthetic control areas following the intervention.[33]

The weights are calculated using the raking [34] method so that the weighted averages for all the variables outlined above in the synthetic control group were the same as for the intervention group. The weighting algorithm derives weights that meet two constraints. Firstly, the sum of first-dose vaccines in the control group equals first-dose vaccines administered in the intervention areas for each of the seven weeks prior to the intervention (Appendix 4). The total number of the first dose administered at the end of the pre-intervention period is matched automatically as the sum of two matched variables (the cumulative number of the first dose administered at the start of the pre-intervention and the weekly number of the first dose administered within the pre-intervention period). It would co-linear with two variables above in the algorithm if specifically added to the weighting. Secondly, the weighted average of each local area characteristic, outlined above in the control group equals the average for the intervention areas.[30] Appendix 5 presents the geographical distribution of these weights and illustrates how the synthetic control group is constructed. The estimated effect of the mobile vaccination unit on the weekly number of first doses, was calculated as the difference between the intervention and the (weighted) synthetic control cohorts in the weekly number of vaccines received over a three-week period after the intervention. To estimate the sampling distribution of the treatment effect, and the permuted p-values and 95% confidence intervals, we applied a permutation procedure outlined by Robbins et al. by repeating the analysis through 250 placebo permutations randomly allocating non-intervention LSOAs to the intervention group.[31]

As our area-based analysis could be biased by insufficiently accounting for confounders at the individual level, we additionally conducted analysis using individual-level data on all adults registered with the GP and living in the intervention and non-intervention LSOAs (as defined above), who had been unvaccinated before the mobile vaccination unit first visited their neighbourhood. We used a weighted Poisson regression model with robust sandwich variance estimators, which has been shown to be a valid alternative to the logistic regression model for the analysis of binary outcomes,[35,36] to estimate the relative risk of vaccination by comparing the vaccine rates between these two groups in the three weeks following the intervention. Using a weighted Poisson regression model to estimate this effect without considering the differences between the intervention and non-intervention areas on the aggregate level would potentially underestimate standard errors and p-values, as this would not account for complex aspects of the process used to generate the synthetic control weights for LSOAs. We therefore weighted this regression using the synthetic control weights as highlighted above

1
2
3 1 to account for systematic LSOA-level differences, after additionally controlling for the following
4 individual-level potential confounders: age, sex, ethnicity, health conditions (as defined above),
5 2 whether people were in contact with social care, whether they were paid carers and the travel time
6 3 by car from each person's address to the nearest conventional static vaccination centre. 18.62% and
7 4 0.01% of ethnicity and sex were missing respectively, leaving 233278 records for the main complete
8 5 case analysis.
9 6

10 7 To explore whether the mobile vaccination unit effect differed by deprivation, ethnicity, and age, we
11 8 fitted another weighted Poisson model including interaction terms between the intervention indicator
12 9 (mobile vaccination unit) and IMD tercile within Cheshire and Merseyside, ethnic group, and age group
13 10 respectively (see Appendix 6 and 7 for detailed results). Apart from the sensitivity test of excluding
14 11 ethnicity (Appendix 8) and the two pop-up sites (Appendix 9) from the analysis to assess the potential
15 12 impact of the missing data and two pop-up static sites on our results respectively, we have additionally
16 13 conducted a series of sensitivity tests on the dose effect of distance threshold used to construct the
17 14 intervention and non-intervention areas (Appendix 10), the potential spatial spill-over effect of the
18 15 intervention (Appendix 11), and survival analyses (Appendix 12) to further check the robustness of our
19 16 results.

20 17 ***Patient and public involvement***

21 18 The local authorities delivering the intervention engaged with various community groups in promoting
22 19 the intervention and identifying intervention sites. Patients and the public were, however, not directly
23 20 involved in designing this analysis.

24 21 **Results**

25 22 Figure 1 shows the intervention (yellow) and the non-intervention areas (purple). The red and cyan
26 23 dots represent the mobile and pop-up static vaccination sites respectively. The map in Appendix 5
27 24 shows the weights that were applied to the non-intervention areas to construct the synthetic control.

28 25 **Figure 1 is about here**

29 26 Table 1 presents summary statistics for the intervention and non-intervention areas (see Appendix 3
30 27 for the comparison between the intervention and the rest of Cheshire and Merseyside). The average
31 28 vaccination rate of the first dose was much higher in the non-intervention areas before the
32 29 introduction of the intervention. On average, residents of the non-intervention areas had to travel
33 30 slightly longer to get to the nearest conventional static vaccine site. The intervention areas were
34 31 younger and more deprived, and had a higher proportion of overcrowded households, higher
35 32 proportions of Asian/Asian British and Black/Black British ethnic minority groups, and higher

1 population density. There were no differences in terms of the proportion of mixed ethnicity. As the
 2 matching algorithm achieved an exact match, the *weighted* average of each variable in Table 1 was
 3 identical in the synthetic control to those in the intervention areas.

4 **Table 1. The summary statistics for the intervention and non-intervention areas at the**
 5 **intervention onset in the 7 weeks prior to the introduction of the mobile vaccination unit.**

	Non-intervention areas	Intervention areas
Total population	1495582	338006
% women	50.84	48.92
Population density – people per hectare	38.84	65.11
Mean age	42.71	38.03
% Asian/Asian British	1.10	3.28
% Black/Black British	0.52	2.37
% Mixed people	1.48	1.87
IMD score	28.71	40.38
% households with at least one-bedroom fewer than they need	2.69	4.77
Average travel time by car to the nearest conventional static vaccine site - minutes	4.14	2.83
First dose vaccine uptake among adults (the percentage of adults who have received the first dose of COVID-19 vaccine among the total eligible adult population prior to pre-intervention) (%)	69.28	52.65
Average weekly first dose vaccination rate among adults in the 7 weeks prior to intervention (%)	1.85	1.51
Number of LSOAs	1112	216

6
 7 Figure 2 shows the trend in weekly vaccination rate in the intervention and synthetic control areas,
 8 during a 11-week period (seven weeks before and three weeks after the introduction of the mobile
 9 vaccination unit). For the pre-intervention period, trends were indistinguishable, as the synthetic
 10 control algorithm has achieved an exact match by successfully calibrating the weights. From the time
 11 point of the intervention being introduced, weekly vaccination rates increased from 1.5% to 1.9% in
 12 the intervention areas. Trends in the matched synthetic control areas that were not visited by a mobile
 13 vaccination unit remained fairly flat, with a small decrease in the post-intervention period. From two
 14 weeks post intervention, 95% CIs stopped overlapping.

15 **Figure 2 is about here**

16 Table 2 shows the estimated effect of the mobile vaccination units on weekly vaccination rate, the
 17 percentage of adults who have received the first dose of the COVID-19 vaccine in each week among
 18 the total eligible adult population, using two models based on area-level and individual-level data

1 respectively. The two analyses show similar results. The area-based analysis indicates that vaccination
 2 rates in the neighbourhoods visited by mobile vaccination units were 23% higher in the three weeks
 3 after the first visit, compared to what would have been the case without the mobile vaccination units'
 4 visits (RR = 1.23, 95% CI: 1.11 to 1.36). The relative risks adjusted for individual-level characteristics is
 5 slightly higher than that of the area-based model (RR = 1.25, 95% CI: 1.21 to 1.28). This overall effect
 6 size estimates 3723 additional vaccinations over three weeks of follow-up across the study area,
 7 similar to the actual number of people vaccinated in the mobile units (n=3824). Sensitivity tests
 8 excluding ethnicity and the two pop-up sites showed similar results with those of model 2 (see
 9 Appendix 8 and 9 respectively). Whilst sensitivity tests on the distance threshold demonstrated the
 10 spatially sensitive nature of our analysis (Appendix 10), our results are relatively robust against the
 11 spatial spill-over effect once an appropriate distance threshold was chosen (Appendix 11).

12 **Table 2. Estimated effect of mobile vaccination units on weekly vaccination rate (the percentage of**
 13 **adults who have received the first dose of the COVID-19 vaccine in each week among the total**
 14 **eligible adult population), the table shows the relative risks indicating the estimated ratio of vaccine**
 15 **rates in the intervention group compared to the synthetic control group in the 3 weeks following**
 16 **intervention. Model 1 uses LSOA level data, accounting for area-based differences between**
 17 **intervention and non-intervention areas, with permuted p-values and confidence intervals. Whilst**
 18 **model 2 additionally controls for individual differences between intervention and non-intervention**
 19 **groups.**

	RR	95% CI		p-value
		LCL	UCL	
Model 1. LSOA level synthetic control analysis	1.23	1.11	1.36	<0.001
Model 2. Individual level weighted Poisson regression analysis	1.25	1.21	1.28	<0.001

Note: RR is relative risk. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

20 Interaction analyses investigated effective modification by deprivation, ethnicity, and age (see
 21 Appendix 6). We found lower impact of the mobile vaccination unit on the vaccination rate for the
 22 most deprived areas (p<0.001) compared to more affluent areas, a lower impact for Asian/Asian
 23 British (p=0.006), Black/Black British (p=0.005) or other ethnic groups (p=0.010), compared to
 24 White/White British people, and a lower impact on vaccine uptake for people aged 31–65 compared
 25 to 18–30-year-olds (p<0.001).

26 **Figure 3 is about here**

1
2
3 1 Figure 3 shows the estimated effect of mobile vaccination units on weekly vaccine uptake for all the
4 2 subgroups using the combination of the effect on the reference group (18–30-year-olds of white
5 3 ethnicity living in the least deprived neighbourhoods that were visited by the mobile vaccination unit)
6 4 and the interaction terms for deprivation, ethnicity, and age group. The relative effect of the
7 5 intervention for the reference group is shown in the bottom left cell of Figure 3, indicating that the
8 6 intervention increased vaccine uptake by 68% (RR 1.68). For people of same ethnic and age group but
9 7 living in intermediately deprived areas, the effect was slightly larger (RR 1.82, 82% increase;
10 8 calculated as the combination of the effect on the reference group and the interaction term for
11 9 intermediate deprivation with mobile vaccination units: $1.683 \times 1.081 = 1.82$; see Appendix 6), whilst for
12 10 those living in the most deprived areas it was lower (RR 1.30, 30% increase; calculated as 1.683×0.770
13 11 in the same manner as above). Effects of other subgroups could be interpreted in the same way. Due
14 12 to the small sample sizes of these 45 subgroups (see Appendix 7), these results should be treated with
15 13 caution. However, they indicate the likely pattern of effects of the intervention across these groups.
16 14 Overall, White, 18–30-year-olds living in neighbourhoods of intermediated deprivation appeared to
17 15 benefit the most from visits of the mobile vaccination unit (Figure 3). Effects were lowest for older age
18 16 groups in the most deprived areas. Although the effect of the mobile vaccination unit may be lower
19 17 for the most deprived population and for people from Black, Asian, and other ethnic minority groups,
20 18 the mobile vaccination unit does still appear to have increased uptake in these groups, particularly for
21 19 younger people. The survival analysis showed similar results overall (Appendix 12).

20 Discussion

21 Our study presents much-needed empirical evidence of the effectiveness of mobile vaccination units
22 in promoting COVID-19 vaccination, indicating that they can increase uptake in their targeted
23 neighbourhoods. The effect size estimated in our analysis closely corresponds to the actual number,
24 indicating that a significant proportion of vaccinations conducted in the mobile units were additional.
25 Put simply, our findings suggest that among individuals utilising the mobile vaccination units, there
26 was a minimal number who would have otherwise sought their vaccinations at conventional static
27 centres. This implies that the mobile vaccination units effectively reached individuals who may have
28 faced barriers in accessing conventional static vaccination sites. Our study therefore also lends support
29 to previous studies on other forms of preventative care that mobile units are useful tools in improving
30 geographical accessibility and convenience of services for patients.[12–15]

31 Within those neighbourhoods, however, the intervention tended to increase uptake most amongst
32 younger people, white people and less socioeconomically deprived areas. However, the targeted
33 neighbourhoods were the most deprived. Our analysis indicated that the intervention was similarly
34 effective in the least deprived and intermediate levels of deprivation *within* these targeted

1
2
3 1 neighbourhoods. It is only in areas with IMD score of over 53, the lower bound of the most deprived,
4 2 that the effectiveness declined. However, 53 is at the 95th percentile of the national distribution of
5 3 IMD scores, representing very deprived areas nationwide. Our findings indicate therefore that the
6 4 intervention was effective at increasing uptake amongst young people in relatively deprived areas
7 5 (although not in extremely deprived areas) and across young people from all ethnic groups in these
8 6 areas.

9
10 7 Our study has limitations. We only had data on individuals who had been registered with the GP at
11 8 time of our study. The GP registered population is larger than that of the 2021 Census (2.7 million vs.
12 9 2.5 million people) due to known data issues (e.g., delays in people updating addresses when move
13 10 home, different definitions of resident population). Although unregistered people attending for
14 11 mobile units were encouraged and can register with a GP in their attendance, there may have been
15 12 people vaccinated who did not wish to be registered, such as undocumented immigrants, homeless
16 13 populations, travellers, and displaced people. We were unable to estimate the impact of the
17 14 intervention in these groups. The mobile vaccination unit could have increased uptake due to
18 15 improved accessibility through the mobile vaccination unit itself and/or the awareness raising and
19 16 publicity associated with visits of these units. Our analysis cannot distinguish between these effects.

20
21 17 Our analysis covers a relatively short period of follow-up. We are therefore unable to determine
22 18 whether the observed effect is due to people being vaccinated earlier than they would otherwise have
23 19 been or if they would have never taken up vaccine without the intervention. We could link
24 20 approximate but not exact time/date visits of the mobile units. Further research should look to
25 21 evaluate if mobile units had different effects at different stages of a pandemic (e.g., initial roll out
26 22 compared to re-opening of society or once most people have been vaccinated by traditional means).
27 23 We used a measure of average distance to construct the intervention and non-intervention group,
28 24 which would have made our effect estimate more conservative (see Appendix 11). Although we have
29 25 accounted for observed differences between places visited by the mobile vaccination units and those
30 26 not and differences in individual characteristics, it is still possible that unmeasured confounding could
31 27 bias the results.

32 28 **Conclusion**

33 29 Our study has implications for strategies aiming to increase vaccine uptake. By improving geographic
34 30 accessibility and convenience of services, the mobile vaccination unit likely promoted uptake of the
35 31 first dose of the COVID-19 vaccine in our study population. The evidence indicating greater effects in
36 32 less deprived areas and in the White/White British population raises concerns that the intervention
37 33 could however lead to an increase in inequalities in uptake within targeted areas. It is important to

1
2
3 1 ensure the mobile vaccination units are effectively targeted to the communities with low uptake and
4
5 2 combined with comprehensive engagement and outreach with Black and Asian ethnic groups and with
6
7 3 more socioeconomically disadvantaged communities. With successive SARS-CoV-2 variants and the
8
9 4 need for multiple vaccine doses to achieve sufficient immunity, rapidly increasing uptake and reducing
10
11 5 inequalities in uptake was of critical public health importance. Deployment of mobile units alongside
12
13 6 other effective approaches to increase uptake in disadvantaged groups can contribute to this goal.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **Transparency statement**

2 The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of
3 the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the
4 study as originally planned (and, if relevant, registered) have been explained.
5

6 **Author contribution statement**

7 B.B. conceived the original idea, devised the project, the main conceptual ideas and proof outline. X.Z. contributed to the
8 literature review, collected the data, and carried out the data analysis. R.A. conducted the initial literature review. X.Z.
9 drafted the manuscript and designed the figures with support from B.B. and M.G.. J.T., S.K. and P.P. assisted with the data
10 access and commented on the manuscript. R.P. assisted in coding. M.GF and M.G. aided in commenting on the manuscript.
11 I.B. aided in supervising the project and commented on the manuscript. S.B. helped to improve the language and
12 visualisation. All authors provided critical feedback and helped to shape the research manuscript.
13

14 **Conflicts of interest statement**

15 We have no conflicts of interest to disclose.
16

17 **Ethics statements**

18 Patient consent for publication

19 Not required.
20

21 **Ethics approval**

22 University Research Ethics Committee review is not required by the University of Liverpool for the secondary analysis of data
23 which have been anonymised by an external party and are provided to the research team in a fully anonymised format.
24

25 **Data sharing statement**

26 The individual-level data is sensitive and could not be shared. But statistical codes are available from
27 <https://github.com/civicdatacoop/mobileVaxUnit>.
28

29 **Funding**

30 This research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in
31 Gastrointestinal Infections (ref NIHR200910), the NIHR Policy Research Programme (RESTORE; Award ID, NIHR202484), the
32 NIHR Applied Research Collaboration Northwest Coast (NWC ARC), and The Pandemic Institute (formed of seven founding
33 partners: The University of Liverpool, Liverpool School of Tropical Medicine, Liverpool John Moores University, Liverpool City
34 Council, Liverpool City Region Combined Authority, Liverpool University Hospital Foundation Trust, and Knowledge Quarter
35 Liverpool). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of
36 Health and Social Care, Public Health England, or The Pandemic Institute.
37

1
2
3 **1 References**
4

- 5 2 1 WHO | Vaccination greatly reduces disease, disability, death and inequity worldwide. WHO.
6 3 <https://www.who.int/bulletin/volumes/86/2/07-040089/en/> (accessed 3 Jun 2021).
7
- 8 4 2 Baraniuk C. Covid-19: How the UK vaccine rollout delivered success, so far. *BMJ* 2021;**372**:n421.
9 5 doi:10.1136/bmj.n421
- 10 6 3 Campos-Matos I, Mandal S, Yates J, *et al.* Maximising benefit, reducing inequalities and ensuring
11 7 deliverability: Prioritisation of COVID-19 vaccination in the UK. *Lancet Reg Health-Eur* 2021;**2**.
12
- 13 8 4 Razai MS, Osama T, McKechnie DG, *et al.* Covid-19 vaccine hesitancy among ethnic minority
14 9 groups. British Medical Journal Publishing Group 2021.
- 15 10 5 Osama T, Razai MS, Majeed A. COVID-19 vaccine allocation: addressing the United Kingdom's
16 11 colour-blind strategy. *J R Soc Med* 2021;:01410768211001581.
- 17 12 6 Collaborative TO, MacKenna B, Curtis HJ, *et al.* Trends, regional variation, and clinical
18 13 characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million
19 14 patients using OpenSAFELY. *medRxiv* 2021;:2021.01.25.21250356.
20 15 doi:10.1101/2021.01.25.21250356
- 21 16 7 Vaccine Coverage - Third/Booster Doses | OpenSAFELY: Reports.
22 17 <http://reports.opensafely.org/reports/vaccine-coverage-thirdbooster-doses/> (accessed 21 Dec
23 18 2021).
- 24 19 8 £22.5m of funding announced in new community push to get nation boosted now. GOV.UK.
25 20 [https://www.gov.uk/government/news/225m-of-funding-announced-in-new-community-push-](https://www.gov.uk/government/news/225m-of-funding-announced-in-new-community-push-to-get-nation-boosted-now)
26 21 [to-get-nation-boosted-now](https://www.gov.uk/government/news/225m-of-funding-announced-in-new-community-push-to-get-nation-boosted-now) (accessed 20 Dec 2021).
27
- 28 22 9 Final report on progress to address COVID-19 health inequalities. GOV.UK.
29 23 [https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-](https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-health-inequalities/final-report-on-progress-to-address-covid-19-health-inequalities)
30 24 [health-inequalities/final-report-on-progress-to-address-covid-19-health-inequalities](https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-health-inequalities/final-report-on-progress-to-address-covid-19-health-inequalities) (accessed
31 25 21 Dec 2021).
32
- 33 26 10 ECDC. Facilitating vaccination acceptance and uptake in the EU/EEA. Stockholm: : ECDC 2021.
34 27 [https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-](https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-acceptance-and-uptake)
35 28 [acceptance-and-uptake](https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-acceptance-and-uptake)
- 36 29 11 Armocida B, Formenti B, Missoni E, *et al.* Challenges in the equitable access to COVID-19
37 30 vaccines for migrant populations in Europe. *Lancet Reg Health – Eur* 2021;**6**.
38 31 doi:10.1016/j.lanepe.2021.100147
- 39 32 12 Williams EM, Vessey MP. Randomised trial of two strategies offering women mobile screening
40 33 for breast cancer. *BMJ* 1989;**299**:158–9.
- 41 34 13 Greenwald ZR, El-Zein M, Bouten S, *et al.* Mobile Screening Units for the Early Detection of
42 35 Cancer: A Systematic Review. *Cancer Epidemiol Biomarkers Prev* 2017;**26**:1679–94.
43 36 doi:10.1158/1055-9965.EPI-17-0454
- 44 37 14 Reuben DB, Bassett LW, Hirsch SH, *et al.* A Randomized Clinical Trial to Assess the Benefit of
45 38 Offering On-Site Mobile Mammography in Addition to Health Education for Older Women. *Am J*
46 39 *Roentgenol* 2002;**179**:1509–14. doi:10.2214/ajr.179.6.1791509

- 1
2
3 1 15 Shima A, Tanaka H, Okamura T, *et al.* Offering on-site mammography in workplaces improved
4 2 screening rates: Cluster randomized controlled trial. *J Occup Health* 2023;**65**:e12389.
5 3 doi:10.1002/1348-9585.12389
6
7 4 16 Freeman D, Loe BS, Yu L-M, *et al.* Effects of different types of written vaccination information on
8 5 COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised
9 6 controlled trial. *Lancet Public Health* 2021;**0**. doi:10/gk725x
10
11 7 17 Dai H, Saccardo S, Han MA, *et al.* Behavioural nudges increase COVID-19 vaccinations. *Nature*
12 8 2021;**597**:404–9. doi:10/gqtk
13
14 9 18 Marquez C, Kerkhoff AD, Naso J, *et al.* A multi-component, community-based strategy to
15 10 facilitate COVID-19 vaccine uptake among Latinx populations: From theory to practice. *PLOS*
16 11 *ONE* 2021;**16**:e0257111. doi:10/gn2bbs
17
18 12 19 Gupta PS, Mohareb AM, Valdes C, *et al.* Expanding COVID-19 vaccine access to underserved
19 13 populations through implementation of mobile vaccination units. *Prev Med* 2022;**163**:107226.
20 14 doi:10.1016/j.ypmed.2022.107226
21
22 15 20 Ecartot F, Maggi S, Michel J-P. Strategies to improve vaccine uptake throughout adulthood.
23 16 *Vaccines Older Adults Curr Pract Future Oppor* 2020;**43**:234–48.
24
25 17 21 Arthur AJ, Matthews RJ, Jagger C, *et al.* Improving uptake of influenza vaccination among older
26 18 people: a randomised controlled trial. *Br J Gen Pract* 2002;**52**:717–22.
27
28 19 22 Hull S, Hagdrup N, Hart B, *et al.* Boosting uptake of influenza immunisation: a randomised
29 20 controlled trial of telephone appointing in general practice. *Br J Gen Pract* 2002;**52**:712–6.
30
31 21 23 Humiston SG, Bennett NM, Long C, *et al.* Increasing inner-city adult influenza vaccination rates: a
32 22 randomized controlled trial. *Public Health Rep* 2011;**126**:39–47.
33
34 23 24 Krieger JW, Castorina JS, Walls ML, *et al.* Increasing influenza and pneumococcal immunization
35 24 rates: a randomized controlled study of a senior center–based intervention. *Am J Prev Med*
36 25 2000;**18**:123–31.
37
38 26 25 Leung KC, Mui C, Chiu WY, *et al.* Impact of patient education on influenza vaccine uptake among
39 27 community-dwelling elderly: a randomized controlled trial. *Health Educ Res* 2017;**32**:455–64.
40
41 28 26 Siriwardena AN, Rashid A, Johnson MR, *et al.* Cluster randomised controlled trial of an
42 29 educational outreach visit to improve influenza and pneumococcal immunisation rates in
43 30 primary care. *Br J Gen Pract* 2002;**52**:735–40.
44
45 31 27 Chan SS, Leung DY, Leung AY, *et al.* A nurse-delivered brief health education intervention to
46 32 improve pneumococcal vaccination rate among older patients with chronic diseases: a cluster
47 33 randomized controlled trial. *Int J Nurs Stud* 2015;**52**:317–24.
48
49 34 28 CIPHA -. <https://www.cipha.nhs.uk/> (accessed 21 Dec 2021).
50
51 35 29 Best J. How the JCVI sets who gets a covid-19 vaccine and when. *BMJ* 2021;**373**:n820.
52 36 doi:10/gpv8m2
53
54
55
56
57
58
59
60

- 1
2
3 1 30 Robbins MW, Davenport S. microsynth: Synthetic Control Methods for Disaggregated and Micro-
4 2 Level Data in R. *J Stat Softw Vol 1 Issue 2 2021* Published Online First: 14 January
5 3 2021. <https://www.jstatsoft.org/v097/i02>
6
7 4 31 Robbins MW, Saunders J, Kilmer B. A Framework for Synthetic Control Methods With High-
8 5 Dimensional, Micro-Level Data: Evaluating a Neighborhood-Specific Crime Intervention. *J Am*
9 6 *Stat Assoc* 2017;**112**:109–26. doi:10/f9746k
11
12 7 32 Barr B, Zhang X, Green M, *et al.* A blueprint for synthetic control methodology: a causal
13 8 inference tool for evaluating natural experiments in population health. *bmj* 2022;**379**.
14
15 9 33 Zhang X, Owen G, Green M, *et al.* Evaluating the Impacts of Tiered Restrictions Introduced in
16 10 England, During October and December 2020 on COVID-19 Cases: A Synthetic Control Study.
17 11 Rochester, NY: : Social Science Research Network 2021. doi:10.2139/ssrn.3805859
18
19 12 34 Raking. In: *Encyclopedia of Survey Research Methods*. 2455 Teller Road, Thousand
20 13 Oaks California 91320 United States of America: : Sage Publications, Inc. 2008.
21 14 doi:10.4135/9781412963947.n433
22
23 15 35 Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. *Am J*
24 16 *Epidemiol* 2004;**159**:702–6. doi:10/cjn5zq
25
26 17 36 Greenland S. Model-based estimation of relative risks and other epidemiologic measures in
27 18 studies of common outcomes and in case-control studies. *Am J Epidemiol* 2004;**160**:301–5.
28 19 doi:10/c6nd87
29
30
31 20
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1. Location of the 35 eligible mobile vaccination units (red dots), the two static pop-up sites**
4 **(cyan dots), and the non-intervention (purple) and intervention (yellow) areas across Cheshire and**
5 **Merseyside. The sub-map in the box of the top right shows the location of Cheshire and**
6 **Merseyside in England.**
7
8
9

10 **Figure 2. The trend in the weekly vaccination rate with their 95% confidence intervals in the**
11 **intervention and synthetic control areas.**
12
13

14
15 **Figure 3. Heatmap of the estimated impact of the mobile vaccination units upon weekly number of**
16 **first dose COVID-19 vaccines administered among all the subgroups based on interaction analysis.**
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Location of the 35 eligible mobile vaccination units (red dots), the two static pop-up sites (cyan dots), and the non-intervention (purple) and intervention (yellow) areas across Cheshire and Merseyside. The sub-map in the box of the top right shows the location of Cheshire and Merseyside in England

2257x1975mm (72 x 72 DPI)




Figure 2. The trend in the weekly vaccination rate with their 95% confidence intervals in the intervention and synthetic control areas.

2257x1975mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Heatmap of the estimated impact of the mobile vaccination units upon weekly number of first dose COVID-19 vaccines administered among all the subgroups based on interaction analysis.

2257x1975mm (72 x 72 DPI)

Appendices

Appendix 1. Timeline of the age eligibility for the rollout of the COVID-19 vaccine programme for the first dose in England.

Table A1. The availability of vaccine appointments for the first dose of COVID-19 vaccine in England, by date.

Start date	Appointments available for
8 December 2020	Residents in a care home for older adults and their carers; and all aged 80 and over
Procedures set out on 9 and 14 January 2021	Frontline health and social care workers
18 January 2021	All aged 70 and over, and clinically extremely vulnerable individuals
15 February 2021	All aged 65 and over; and those aged 16 to 64 with underlying health conditions which put them at higher risk of serious disease and mortality
1 March 2021	All aged 60 and over
6 March 2021	All aged 56 and over
17 March 2021	All aged 50 and over
13 April 2021	All aged 45 and over
26 April 2021	All aged 44 and over
27 April 2021	All aged 42 and over
30 April 2021	All aged 40 and over
13 May 2021	All aged 38 and over
18 May 2021	All aged 36 and over
20 May 2021	All aged 34 and over
22 May 2021	All aged 32 and over
26 May 2021	All aged 30 and over
8 June 2021	All aged 25 and over
15 June 2021	All aged 23 and over
16 June 2021	All aged 21 and over
18 June 2021	All adults (namely aged 18 and over)

Source: [COVID-19 vaccination in the United Kingdom - Wikipedia](#).

Appendix 2. Crude and age-adjusted accumulated uptake of the COVID-19 vaccine first dose in Cheshire and Merseyside between the 49th week of 2020 (6th to 12th December 2020; the first COVID-19 vaccine was administered in the UK on 8th December 2020) and the 29th week of 2021 (18th to 24th July 2021; the end point of our study is 19th July 2021, three weeks after the last mobile vaccination unit visit on 28th June 2021).




Figure A1. Crude accumulated uptake rate of the first dose COVID-19 vaccine across Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021, the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). After a relatively linear and stable growth between the 1st and 7th week of 2021, Cheshire and Merseyside started to see signs of slowing down in the crude uptake rate since the 8th week of 2021 (21st to 27th February 2021).







Figure A2. Average crude accumulated uptake rate of the first dose COVID-19 vaccine across all lower layer super-output areas (LSOAs) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021, with its 95% confidence intervals. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), LSOAs of Cheshire and Merseyside had seen expanding variations in their crude accumulated uptake of the first dose COVID-19 vaccine.




A3. Crude accumulated uptake rate of the first dose COVID-19 vaccine among ethnic groups (White, Asian or Asian British, Black or Black British, Mixed, and Other) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), ethnic groups of Cheshire and Merseyside had seen widening gaps in their crude accumulated uptake of the first dose COVID-19 vaccine.



A4. Age-adjusted accumulated uptake rate of the first dose COVID-19 vaccine among ethnic groups (White, Asian or Asian British, Black or Black British, Mixed, and Other) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). The 8th week of 2021 (21st to 27th February 2021), as a turning point, had become pronounced for widening gaps in age-adjusted accumulated uptake of the first dose COVID-19 vaccine among ethnic groups in Cheshire and Merseyside.



A5. Crude accumulated uptake rate of the first dose COVID-19 vaccine among different socio-economic groups (Least deprived, Intermediate deprivation, and Most deprived) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), different socio-economic groups of Cheshire and Merseyside had seen increasingly growing gaps in their crude accumulated uptake of the first dose COVID-19 vaccine.



A6. Age-adjusted accumulated uptake rate of the first dose COVID-19 vaccine among different socio-economic groups (Least deprived, Intermediate deprivation, and Most deprived) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), different socio-economic groups of Cheshire and Merseyside had seen signs of widening gaps in their age-adjusted accumulated uptake of the first dose COVID-19 vaccine.




Figure A7. Crude accumulated uptake rate of the first dose COVID-19 vaccine by local authorities in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021, the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021).

Appendix 3. Summary statistics of the intervention and full non-intervention population at the intervention onset in the 7 weeks prior to the introduction of the mobile vaccination unit.

Whilst Table 1 presents summary statistics for the intervention and non-intervention areas within the eight local authorities that reported data on the deployment (or non-deployment) of the mobile vaccination units and therefore are used to conduct the main analysis, Table A2 below shows the comparison between the intervention and the rest of the Cheshire and Merseyside, including the eight local authorities above and the one local authority with missing data on the intervention that has been excluded from the main analysis.

Table A2. The comparison between the intervention and the rest of Cheshire and Merseyside at the intervention onset in the 7 weeks prior to the introduction of the mobile vaccination unit.

	Rest of the Cheshire and Merseyside region	Intervention areas
Total population	1829809	338006
% women	50.72	48.92
Population density – people per hectare	34.88	65.11
Mean age	42.72	38.03
% Asian/Asian British	1.20	3.28
% Black/Black British	0.52	2.37
% Mixed people	1.39	1.87
IMD score	25.83	40.38
% households with at least one-bedroom fewer than they need	2.55	4.77
Average travel time by car to the nearest conventional static vaccine site - minutes	4.28	2.83
First dose vaccine uptake among adults (the percentage of adults who have received the first dose of COVID-19 vaccine among the total eligible adult population prior to pre-intervention) (%)	66.15	52.65

Average weekly first dose vaccination rate among adults in the 7 weeks prior to intervention (%)	2.08	1.51
Number of LSOAs	1346	216

For peer review only

Appendix 4. The weekly number of the first dose administered in the intervention and control groups for each of the seven weeks prior to the intervention (the mobile vaccination unit).

Table A3. Weekly number of the first dose administered in the intervention and control groups for each of the seven weeks prior to the intervention (the mobile vaccination unit).

Weeks before the intervention	Weekly number of the first dose administered in the LSOAs being visited by the mobile vaccination units	Weekly number of the first dose administered in the LSOAs in the rest of Cheshire & Merseyside used to construct the synthetic control	Weekly number of the first dose administered in the synthetic control (weighting LSOAs in the rest of Cheshire & Merseyside using synthetic control weights)
7	5692	31995	5692
6	5040	29288	5040
5	5256	31869	5256
4	5537	33022	5537
3	4730	24901	4730
2	4493	21180	4493
1	5059	21685	5059

Appendix 5. Geographical pattern of weights in area-based synthetic control analysis.




Figure A8. Weighting of areas outside of the catchment of the mobile vaccination units to construct the synthetic control group. Areas within the catchment of the mobile vaccination units are coloured black, whilst locations of the mobile vaccination unit are represented by red (35 mobile sites) and cyan (two static pop-up sites) dots. The white non-intervention areas are those that have been allocated zero weights in constructing the synthetic control, whilst other coloured non-intervention areas are those with non-zero weights in constructing the synthetic control: the darker the colour, the larger the weight.

Appendix 6. Regression output for the interaction model based on adult individuals.

Subgroup analysis by deprivation, ethnicity and age indicates, lower impact of the mobile vaccination unit on vaccination uptake for the most deprived areas compared to more affluent areas, a lower impact for Asian/Asian British, Black/Black British or Other ethnic groups, compared to white British people, and a lower impact on people aged 31-65-year-olds. The sample sizes are quite low for the subgroup analysis (see Appendix 7 below for more details) so the results reported here are only indicative of the overall pattern. Table A4 below shows the effect sizes of the mobile vaccination unit for the subgroups as relative risks. Compared to people not visited by the mobile vaccination units in their neighbourhoods, visits of the mobile vaccination units have increased vaccination rates in the following groups: people aged 18-30 from all socio-economic backgrounds and all ethnic groups except for Black/Black British; White/White British people aged above 30 from least and intermediate deprived areas; people aged 30-65 of mixed and other ethnic groups from the intermediate deprived areas; and people aged above 65 of mixed and other ethnic groups from least and intermediate deprived areas (see Figure 3 in the main text for more details).

Table A4. Regression output with interaction terms based on adult individuals. The table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention.


Variables	RR	95% CI		p-value
		LCL	UCL	
Mobile vaccination unit (reference: no mobile vaccination unit)	1.683	1.584	1.789	<0.001
Age group (reference: 18-30 years old)				
(30,65]	1.249	1.187	1.313	<0.001
65+	0.201	0.147	0.275	<0.001
Sex (reference: Women)				
Men	1.013	0.984	1.042	0.380
Ethnicity (reference: White/White British)				
Asian/Asian British	0.919	0.791	1.068	0.271
Black/Black British	0.749	0.605	0.929	0.008
Mixed	0.746	0.608	0.915	0.005
Other ethnic groups	0.799	0.746	0.856	<0.001
IMD tercile (reference: Least deprived)				
Intermediate deprivation	0.786	0.741	0.834	<0.001
Most deprived areas	0.673	0.631	0.718	<0.001
Chronic health conditions (reference: none)	1.098	1.076	1.120	<0.001
Carer (reference: not carer)	0.320	0.273	0.375	<0.001
Social care receiver (reference: not social care receiver)	0.979	0.764	1.255	0.869
Travel time by car to the nearest static vaccine centre (minutes)	1.087	1.082	1.093	<0.001
Interaction between age groups and mobile vaccination unit (reference: 18-30 years old with mobile vaccination unit)				
30-65 years old with mobile vaccination unit	0.638	0.602	0.676	<0.001
65+ years old with mobile vaccination unit	0.700	0.475	1.030	0.070
Interaction between ethnicity and mobile vaccination unit (reference: White/White British with mobile vaccination unit)				
Asian/Asian British with mobile vaccination unit	0.788	0.664	0.935	0.006
Black/Black British with mobile vaccination unit	0.704	0.550	0.901	0.005

Mixed with mobile vaccination unit	0.900	0.712	1.138	0.379
Other ethnic groups with mobile vaccination unit	0.903	0.835	0.976	0.010
Interaction between IMD tercile and mobile vaccination unit (reference: Least deprived with mobile vaccination unit)				
Intermediate deprivation with mobile vaccination unit	1.081	1.010	1.158	0.024
Most deprived areas with mobile vaccination unit	0.770	0.715	0.829	<0.001
Note: The intercept is excluded from the output. We reported the result in three decimal digits specifically here to facilitate the explanation on how to interpret interaction terms.				

For peer review only

Appendix 7. Sample size of the sub-groups (with visits of the mobile vaccination units) in the weighted Poisson model including interaction terms between the intervention indicator (mobile vaccination unit) and IMD tercile within Cheshire and Merseyside, ethnic and age groups respectively.

Figure A10. Heatmap of the sample size for each subgroup receiving the visit of the mobile vaccination units based on interaction analysis.



Appendix 8. Sensitivity test – excluding ethnicity from the main model.

Table A5. Results of analysis for adult individuals of all ages, excluding ethnicity.

	RR	95% CI		p-value
		LCL	UCL	
Model 2a. Individual level weighted Poisson regression analysis	1.24	1.21	1.28	<0.001

Results of individual-level analysis presented in Table A5 and Table 2 are almost identical, implying that excluding cases with missing information on ethnicity did not affect the robustness of our results.

Appendix 9. Sensitivity test – excluding the two pop-up sites across C&M.

Table A6. Results of analysis for adult individuals of all ages, excluding the two pop-up sites.

	RR	95% CI		p-value
		LCL	UCL	
Model 2b. Individual level weighted Poisson regression analysis	1.23	1.18	1.29	<0.001

Table A6 of individual-level analysis shows very similar results to those of Table 2, indicating that it is unlikely that the use of the two pop-up sites rather than vaccine buses alone influenced our results overall.

Appendix 10. Sensitivity test – results of the synthetic control method based on different distance thresholds in constructing the synthetic control.

Table A7. Estimated effect of mobile vaccination units on weekly vaccine uptake (the percentage of adults who have received the first dose of the COVID-19 vaccine in a given week among the total eligible adult population), the table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention. Model 1a uses the 500 meter distance threshold to construct the intervention and non-intervention areas with LSOA level data, accounting for area-based differences between intervention and non-intervention areas, with permuted p-values and confidence intervals. Model 1b, 1c and 1d use the distance threshold of 1, 2 and 3KM respectively, all else equal.

	RR	95% CI		p-value
		LCL	UCL	
Model 1a. LSOA level synthetic control analysis – 500-meter threshold	1.10	-1.04	1.30	0.208
Model 1b. LSOA level synthetic control analysis – 1500-meter threshold	1.15	1.04	1.26	<0.001
Model 1c. LSOA level synthetic control analysis – 2000-meter threshold	1.05	-1.04	1.17	0.280
Model 1d. LSOA level synthetic control analysis – 3000-meter threshold	1.02	-1.12	1.19	0.888

Note: RR is relative risk. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

Appendix 11. Sensitivity test – results of the synthetic control method excluding LSOAs with centroids located between 1 to 1.5 km from the nearest mobile vaccination unit to account for the potential spatial spill over effect.

Table A8. Estimated effect of mobile vaccination units on weekly vaccine uptake (the percentage of adults who have received the first dose of the COVID-19 vaccine in a given week among the total eligible adult population), the table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention. Model 1e uses the same distance threshold (1 km) as the main model 1 to construct the intervention and non-intervention areas with LSOA level data, but excludes LSOAs with population weighted centroids located between 1 and 1.5km from the nearest mobile vaccination unit to additionally account for the potential spatial spill over effect, with permuted p-values and confidence intervals.

	RR	95% CI		p-value
		LCL	UCL	
Model 1e. LSOA level synthetic control analysis – accounting for potential spatial spill over effect between 1 and 1.5 km	1.24	1.11	1.40	<0.001

Note: RR is relative risk. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

Appendix 12. Sensitivity test – results of survival analyses based on adult individuals.

Using weights calibrated in the synthetic control analysis, we conducted a survival analysis to check the robustness of the synthetic control analysis. In this analysis, we compared the survival probability (the probability of adults to stay unvaccinated) between the synthetic control and intervention groups in the three weeks following the intervention, only including unvaccinated adults at the time of the intervention, a binary categorical variable indicating whether an individual had received the first-dose of the COVID-19 vaccine as the outcome variable, the number of week from the intervention as the time variable, and the variable of the intervention (the mobile bus units). Figure A8 below shows the survival curves of two groups and the risk table. Even without controlling for any individual-level confounders used in the main individual-level analysis, this model estimates 3487 additional vaccinations over three weeks of follow-up period ($3487 = (32005 - 47132) - (29878 - 48492)$), broadly in line with the effect size estimated in the main analysis ($n=3723$).




Figure A9. The survival curves of the synthetic control (coloured in purple) and intervention groups (coloured in yellow) with their respective 95% confidence intervals and the risk table, following the same colouring scheme of Figure 2 in the main analysis.

We then used a Cox proportional hazards regression model to replicate the sub-group analysis in Appendix 6. Results are shown in Table A9, similar to Table A4 in the overall trends and patterns.

Table A10. Cox regression output for the interaction model based on adult individuals. The table shows the hazard ratio (HR) indicating the estimated ratio of weekly vaccination rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention.

Variables	HR	95% CI		p-value
		LCL	UCL	
Mobile vaccination unit (reference: no mobile vaccination unit)	1.83	1.72	1.95	<0.001
Age group (reference: 18-30 years old)				
(30,65]	2.16	2.05	2.29	<0.001
65+	1.49	1.08	2.06	0.017
Sex (reference: Women)				
Men	1.07	1.03	1.10	<0.001
Ethnicity (reference: White/White British)				
Asian/Asian British	0.83	0.71	0.98	0.027
Black/Black British	0.90	0.72	1.12	0.344
Mixed	0.77	0.62	0.96	0.021
Other ethnic groups	0.98	0.91	1.05	0.549
IMD tercile (reference: Least deprived)				
Intermediate deprivation	0.92	0.86	0.98	0.008
Most deprived areas	0.94	0.88	1.01	0.090
Chronic health conditions (reference: none)	0.97	0.95	0.99	0.013
Carer (reference: not carer)	0.67	0.56	0.80	<0.001
Social care receiver	1.02	0.79	1.30	0.894
Travel time by car to the nearest static vaccine centre (minutes)	1.04	1.04	1.05	<0.001
Interaction between age groups and mobile vaccination unit (reference: 18-30 years old with mobile vaccination unit)				
30-65 years old with mobile vaccination unit	0.65	0.61	0.69	<0.001
65+ years old with mobile vaccination unit	0.57	0.38	0.85	0.006
Interaction between ethnicity and mobile vaccination unit (reference: White/White British with mobile vaccination unit)				

Asian/Asian British with mobile vaccination unit	0.88	0.73	1.06	0.179
Black/Black British with mobile vaccination unit	0.70	0.54	0.90	0.006
Mixed with mobile vaccination unit	0.98	0.76	1.26	0.879
Other ethnic groups with mobile vaccination unit	0.98	0.91	1.07	0.670
Interaction between IMD tercile and mobile vaccination unit (reference: Least deprived with mobile vaccination unit)				
Intermediate deprivation with mobile vaccination unit	0.91	0.85	0.98	0.013
Most deprived areas with mobile vaccination unit	0.58	0.54	0.63	<0.001

Note: HR is hazard ratio. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
Title and abstract		1-2
Title	#1a Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction		4-5
Background / rationale	#2 Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	#3 State specific objectives, including any prespecified hypotheses	5
Methods		5-9
Study design	#4 Present key elements of study design early in the paper	5-9
Setting	#5 Describe the setting, locations, and relevant dates, including periods of	6-7

recruitment, exposure, follow-up, and data collection

1			
2			
3	Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants. 7-9
4			
5			
6		#7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable 7-9
7			
8			
9			
10	Data sources /	#8	For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for for exposed and unexposed groups if applicable. 5-6
11	measurement		
12			
13			
14			
15			
16			
17	Bias	#9	Describe any efforts to address potential sources of bias 8-9
18			
19	Study size	#10	Explain how the study size was arrived at 9
20			
21	Quantitative	#11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why 5-6
22	variables		
23			
24			
25	Statistical	#12a	Describe all statistical methods, including those used to control for confounding 7-9
26	methods		
27			
28			
29	Statistical	#12b	Describe any methods used to examine subgroups and interactions 9
30	methods		
31			
32			
33	Statistical	#12c	Explain how missing data were addressed 9
34	methods		
35			
36			
37	Statistical	#12d	If applicable, describe analytical methods taking account of sampling strategy
38	methods		
39			
40			
41	Statistical	#12e	Describe any sensitivity analyses 9
42	methods		
43			
44	Results		9-12
45			
46			
47	Participants	#13a	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.
48			
49			
50			
51			
52			
53			
54			
55	Participants	#13b	Give reasons for non-participation at each stage
56			
57	Participants	#13c	Consider use of a flow diagram
58			
59			
60			

1	Descriptive data	#14a	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	9-10
2				
3				
4				
5				
6	Descriptive data	#14b	Indicate number of participants with missing data for each variable of interest	
7				
8				
9				
10	Outcome data	#15	Report numbers of outcome events or summary measures. Give information separately for exposed and unexposed groups if applicable.	10
11				
12				
13				
14	Main results	#16a	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10-11
15				
16				
17				
18				
19	Main results	#16b	Report category boundaries when continuous variables were categorized	
20				
21	Main results	#16c	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	11
22				
23				
24				
25	Other analyses	#17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	11-12
26				
27				
28				
29	Discussion			12-14
30				
31	Key results	#18	Summarise key results with reference to study objectives	12-13
32				
33				
34	Limitations	#19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	13
35				
36				
37				
38				
39	Interpretation	#20	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	13-14
40				
41				
42				
43				
44	Generalisability	#21	Discuss the generalisability (external validity) of the study results	13-14
45				
46				
47	Other			
48	Information			
49				
50				
51	Funding	#22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15
52				
53				
54				
55				

None The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Evaluating the impact of using mobile vaccination units to increase COVID-19 vaccination uptake in Cheshire and Merseyside, UK: A synthetic control analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-071852.R2
Article Type:	Original research
Date Submitted by the Author:	15-Sep-2023
Complete List of Authors:	Zhang, Xingna; University of Liverpool, Department of Public Health, Policy & Systems Tulloch, John; University of Liverpool, HPRU EZI Knott, Shane; Liverpool Liverpool City Council Allison, Rachel; Russells Hall Hospital Parvulescu, Paula; Liverpool City Council Buchan, Iain; University of Liverpool, Public Health and Policy Garcia-Finana, Marta; University of Liverpool, Department of Health Data Science; Clinical Trials Research Centre, Piroddi, Roberta; University of Liverpool, Department of Public Health, Policy & Systems Green, Mark; University of Liverpool, Geography & Planning Baird, Sophie; The UK Health Security Agency Barr, Ben ; University of Liverpool, Department Public Health and Policy
Primary Subject Heading:	Public health
Secondary Subject Heading:	Infectious diseases, Health policy
Keywords:	COVID-19, Public health < INFECTIOUS DISEASES, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **1 Evaluating the impact of using mobile vaccination units to increase COVID-19 vaccination**
4 **2 uptake in Cheshire and Merseyside, UK: A synthetic control analysis.**
5

6 3 Xingna Zhang¹, John Tulloch², Shane Knott³, Rachel Allison⁴, Paula Parvulescu⁵, Iain Buchan⁶, Marta
7 4 García-Fiñana⁷, Roberta Piroddi⁸, Mark A. Green⁹, Sophie Baird¹⁰, Ben Barr¹¹
8

9 5 ¹ Tenure Track Fellow, Department of Public Health, Policy & Systems, University of Liverpool,
10 6 Liverpool, UK

11 7 ² Tenure Track Fellow, Department of Livestock and One Health in the Institute of Infection,
12 8 Veterinary and Ecological Science, University of Liverpool, Liverpool, UK

13 9 ³ Senior Public Health Practitioner (Healthcare), Liverpool City Council, Liverpool, UK

14 10 ⁴ FY1 Doctor, Russells Hall Hospital, Dudley, UK

15 11 ⁵ Consultant in Public Health Medicine, Liverpool City Council, Liverpool, UK

16 12 ⁶ Chair in Public Health and Clinical Informatics, Department of Public Health, Policy & Systems,
17 13 University of Liverpool, Liverpool, UK

18 14 ⁷ Professor of Health Data Science, Department of Health Data Science, University of Liverpool,
19 15 Liverpool, UK

20 16 ⁸ Research Fellow, Department of Public Health, Policy & Systems, University of Liverpool, Liverpool,
21 17 UK

22 18 ⁹ Reader in Health Geography, Department of Geography & Planning, University of Liverpool,
23 19 Liverpool, UK

24 20 ¹⁰ Public Health Registrar, The UK Health Security Agency, UK

25 21 ¹¹ Chair in Applied Public Health Research, Department of Public Health, Policy & Systems, University
26 22 of Liverpool, Liverpool, UK
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 25 Corresponding author:

43 26 Xingna Zhang

44 27 xingna.zhang@liverpool.ac.uk

45 28 WORD COUNT (excluding title page, abstract, figures, tables, references, author statements and
46 29 appendices): 4186

47 30 No of Tables (excluding Appendix): 2

48 31 No of Figures (excluding Appendix): 3

49 32 Supplementary files: 12 appendices at the end of this document
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 **ABSTRACT**
4

5 2 **Objective** To evaluate the impact of mobile vaccination units on COVID-19 vaccine uptake of the first
6
7 3 dose, the percentage of vaccinated people among the total eligible population. We further
8
9 4 investigate whether such an effect differed by deprivation, ethnicity, and age.

10
11 5 **Design** Synthetic control analysis.
12

13 6 **Setting** The population registered with General Practices (GPs) in nine local authority areas in
14
15 7 Cheshire and Merseyside in Northwest England, UK.
16

17 8 **Intervention** Mobile vaccination units that visited 37 sites on 54 occasions between 12th April and
18
19 9 28th June 2021. We defined intervention neighbourhoods as having their population weighted
20
21 10 centroid located within 1km of mobile vaccination sites (338,006 individuals). A weighted
22
23 11 combination of neighbourhoods that had not received the intervention (1,495,582 individuals) was
24
25 12 used to construct a synthetic control group.

26
27 13 **Outcome** The weekly number of first-dose vaccines received among people aged 18 years and over
28
29 14 as a proportion of the population.

30
31 15 **Results** The introduction of a mobile vaccination unit into a neighbourhood increased the number of
32
33 16 first vaccinations conducted in the neighbourhood by 25% (95% CI: 21% to 28%) within three weeks
34
35 17 after the first visit to a neighbourhood, compared to the synthetic control group. Interaction
36
37 18 analyses showed smaller or no effect amongst older age groups, Asian and Black ethnic groups, and
38
39 19 the most socioeconomically deprived populations.

40 20 **Conclusions** Mobile vaccination units are effective interventions for increasing vaccination uptake, at
41
42 21 least in the short-term. While mobile units can be geographically targeted to reduce inequalities, we
43
44 22 found evidence that they may increase inequalities in vaccine uptake within targeted areas, as the
45
46 23 intervention was less effective amongst groups that tended to have lower vaccination uptake.
47
48 24 Mobile vaccination units should be used in combination with activities to maximise outreach with
49
50 25 Black and Asian communities and socioeconomically disadvantaged groups.
51

52
53 26
54

55
56
57 27
58
59
60

1 **Strengths and limitations of this study**

- 2 - The synthetic control method for microdata offers a rigorous method for identifying control
3 areas that experienced similar levels of COVID-19 vaccine uptake as the intervention areas
4 prior to the introduction of mobile vaccination units, supporting a possible causal
5 interpretation of the finding of increased uptake in areas with mobile vaccination visits
6 following their introduction.
- 7 - The use of individual-level data enabled us to construct weighted Poisson regression models
8 to offer robust estimation of the observed effect, with interaction analysis to reveal whether
9 this effect varied by level of deprivation, age groups and ethnicity.
- 10 - We were not able to include individuals that had not been registered with the GP at time of
11 our study, which could lead to the underestimation of the effect given that the main
12 vaccination programme was provided through GPs.
- 13 - As our analysis covers a relatively short follow-up period, the results may not reflect the
14 sustained impact of the intervention over longer periods of time.
- 15 - There may also be other differences between places being visited by the mobile vaccination
16 units and those that were not and differences in individual characteristics, beyond those
17 included in this study, that led to the differences in the observed effect.

1 Introduction

Vaccination is one of the most effective public health interventions for improving health and saving lives.[1] Following the national rollout of the COVID-19 vaccine program on 8th December 2020 in the UK, relatively high vaccine uptake has helped reduce the risk of hospitalisation and mortality from COVID-19.[2] Nevertheless, vaccine uptake was lower among young people, socioeconomically disadvantaged groups and ethnic minorities for a combination of factors including vaccine eligibility (Appendix 1 presents the timeline for age eligibility of the first dose of the COVID-19 vaccine in England) and hesitancy, health disparities and inequalities, convenience and access, language and cultural barriers, and trust in healthcare systems.[3–6] Some of these groups have also often experienced disproportionately greater levels of infections, hospitalisations and deaths during the pandemic. With successive SARS-CoV-2 variants, additional booster vaccinations were needed to give sufficient protection. Inequalities in uptake of these subsequent doses were greater than with the initial doses,[7] potentially undermining responses to new variants that rely largely on increased uptake of booster vaccinations. The UK government invested £22.5 million to help areas increase uptake amongst hard-to-reach groups in December 2021, as tackling health inequalities is a core government priority.[8] A central part of this strategy was to use mobile vaccination units such as pop-up sites and vaccine buses – “taking the vaccines into the hearts of local communities”.[9]

Mobile vaccination units have been used in many countries to increase uptake in disadvantaged communities.[10] These generally involve vaccination clinics based in large vehicles such as buses or temporary pop-up clinics in community settings. As well as bringing vaccines into targeted communities, they usually involve outreach programmes (e.g., leaflet campaigns to advertise vaccination units and explain the benefits of vaccination). The use of mobile vaccination units to increase uptake is based on the premise that geographic accessibility and convenience of vaccination services are potentially important determinants of uptake and that they support uptake from people who have difficulty in accessing existing sites due to information or travel barriers, childcare or healthcare responsibilities, or being excluded from the official healthcare system.[11]

Although former studies found mobile units as useful tools to reduce health inequalities in administering other forms of preventative care such as cancer screening,[12–15] there has been limited research evaluating interventions that aim to increase COVID-19 vaccine uptake. One Randomised Controlled Trial (RCT) shows that provision of information on personal benefit reduces hesitancy,[16] with another RCT indicating that text message reminders lead to small increases in uptake.[17] One study of a community-based strategy in an underserved Latinx population in San Francisco found that mobile units reached their intended recipients, but the study was unable to

1
2
3 1 estimate the impact on vaccination uptake.[18] Another study found that users of the COVID-19
4 2 mobile vaccination units tended to be younger, non-White race, and Hispanic ethnicity compared to
5 3 the general vaccinated populations in the Greater Boston area, suggesting the potential benefits of
6 4 mobile vaccination units without estimating the average treatment effect.[19] A few studies
7 5 investigated the impact of interventions aiming to increase Influenza and pneumococcal vaccination,
8 6 including one systematic review,[20] five RCTs [21–25] and two cluster RCTs.[26,27] Of these, three
9 7 were published in the United Kingdom,[21,22,26] three in the United States [20,23,24] and two in
10 8 Hong Kong.[25,27] They all show that sending out reminders, telephone calls and educational
11 9 outreach tend to increase uptake. We found no studies that quantified the effect of introducing
12 10 mobile vaccination units on COVID-19 vaccine uptake.

13 11 It also remains largely uncertain how effective mobile vaccination units are at increasing uptake
14 12 amongst disadvantaged groups, having been deployed to improve vaccine access for those
15 13 communities.[2,18,19] The lack of existing evidence is concerning, considering their central role in the
16 14 strategies to reduce vaccine uptake inequalities. We therefore used a synthetic control approach to
17 15 investigate the impact of mobile vaccination units in the Northwest of England and how this varied by
18 16 age, socioeconomic status, and ethnicity.

17 **Methods**

18 ***Data***

19 We utilised anonymised electronic health records (EHR) on all people aged 18 and over, registered
20 with a General Practice (GP) in Cheshire and Merseyside, England, between 22nd February and 19th
21 July 2021.[28] This data included vaccination status, vaccination date, age, sex, ethnicity, chronic
22 health conditions diagnosed in primary care (chronic obstructive pulmonary disease, chronic heart
23 disease, diabetes, chronic kidney disease asthma, cancer, obesity, depression, and stroke/transient
24 ischaemic attack), whether people were in contact with social care, whether they were a paid carer,
25 travel time by car to the nearest conventional static vaccination site requiring booking in advance and
26 the Lower Super Output Areas (LSOA) of residence. LSOAs are small geographical areas of England,
27 with approximately 1500 residents each. Ethnicity was based on information of primary care records.
28 Where unavailable, ethnicity was taken from hospital, community, or social care records if available
29 in these datasets. Ethnicity was categorised in these datasets using the 17 standard Office for National
30 Statistics Categories. These were then re-coded to 5 categories for analysis (White/White British,
31 Asian/Asian British, Black/Black British, Mixed, and Other).

1
2
3 1 We linked the EHR data to LSOA-level data, including 2019's indices of multiple deprivation (IMD) – a
4
5 2 composite measure of deprivation across seven domains (income, employment, education, health,
6
7 3 crime, barriers to housing & services, and living environment), an over-crowded housing measure (the
8
9 4 proportion of households with at least one-bedroom fewer than they need) based on 2011's Census,
10
11 5 and population density using 2019's mid-year population estimates from the Office for National
12
13 6 Statistics. The public health teams of the nine local authorities in the Cheshire and Merseyside region
14
15 7 were asked to provide a list of locations and dates of mobile vaccination units in their areas between
16
17 8 May and November 2021. Six local authorities provided this information and two local authorities
18
19 9 reported that they had had no mobile vaccination units. Analysis was therefore limited to these eight
20
21 10 local authorities.

21 ***Intervention***

22
23 12 Six local authorities operated mobile vaccination units, that visited 37 sites on 54 occasions, between
24
25 13 12th April and 28th June 2021. This included 52 visits from vaccine buses and two from two pop-up
26
27 14 static clinics (different from conventional static vaccination sites, these two pop-up sites offered walk-
28
29 15 in services without the need to book in advance). Six sites were visited more than once during our
30
31 16 study period, with repeated visits scheduled either consecutively or at least one week apart. Vaccines
32
33 17 were offered typically from 9am to 4.30pm or 5pm on the day of most visits, with four visits operating
34
35 18 from 8am to 6pm, 9am to 3pm, 9.15am to 2.30pm and 10am to 2pm respectively. We chose to treat
36
37 19 all sites uniformly in our analysis to avoid potentially overemphasising the impact of sites with multiple
38
39 20 visits and minimise the potential influence of site-specific factors. This simplifying assumption offers
40
41 21 us a more conservative approach and allows us to focus on the overall effect of the intervention rather
42
43 22 than site-specific variations, thus enabling clearer interpretation and generalisability of the results.
44
45 23 The deployment of the mobile vaccination units also involved outreach programmes to advertise
46
47 24 vaccination units and explain the benefits of vaccination for each visit. Units were primarily focused
48
49 25 on offering first-dose COVID-19 vaccinations to those that had not received a vaccine at any of the
50
51 26 city's existing conventional static vaccination sites and were eligible for vaccination at the time.[29]
52
53 27 Vaccines were offered on a drop-in basis with no appointment needed. The number of vaccinations
54
55 28 received at these mobile units was unavailable for one local authority (Warrington). The total number
56
57 29 of first dose vaccinations for the remaining five local authorities that had deployed the mobile
58
59 30 vaccination units was 3824. Sites visited by mobile vaccination units were identified by local public
60
31 health and health service teams based on their knowledge of vaccine uptake (i.e., the percentage of
32 adults who have received the first dose of the COVID-19 vaccine among the total eligible adult
33 population in our study), practicalities of having space and permissions to locate the vaccination unit,
34 and relationships with local community groups.

1 We defined intervention neighbourhoods as having their population weighted centroid located within
2 1km of mobile vaccination sites and identified 216 LSOAs that were either hosts for mobile vaccination
3 units or had population weighted centroids within a 1km radius of mobile vaccination units. We
4 calculated the start time of the intervention as the week a mobile vaccination unit first visited. This
5 left 1112 non-intervention LSOAs within the eight participating local authorities that did not have
6 population weighted centroids within 1km of a mobile unit. We then applied a 'placebo' start time to
7 each of these non-intervention LSOAs, generated uniformly at random in the same weekly proportion
8 as the distribution of intervention start dates for the intervention LSOAs.

9 ***Statistical analysis***

10 We aggregated the individual-level data to construct a panel of weekly measures at the LSOA level
11 from seven weeks (22nd February 2021) before the first mobile vaccination unit visit on 12th April 2021
12 to three weeks (19th July 2021) after the last mobile vaccination unit visit on 28th June 2021. We chose
13 seven weeks as our pre-intervention period after evaluating trends of the accumulated uptake, overall
14 and by ethnic and socio-economic groups, with consideration of the rollout of the vaccine prioritised
15 by age groups (Appendix 1 and 2). A seven-week pre-intervention period allowed us to capture trends
16 for most people eligible for the vaccine and focus on the intervention at a relatively stable stage of
17 the pandemic. We then chose a three-week follow-up period due to the policy change in July 2021 to
18 prioritise administering the second doses. A three-week period avoided spill-over effect of this
19 prioritisation and allowed us to estimate the effect of repeated visits in some sites and the
20 accompanying outreach programmes. We therefore aimed to investigate the short-term effect of the
21 intervention here. The weekly panel data included LSOA-level measures of total GP registered
22 population size, the proportion of Black/Black British people, the proportion of Asian/Asian British
23 people, the proportion of people of mixed ethnicity, mean age of residents, population density, the
24 proportion of women, the IMD score, the proportion of households living in overcrowded housing,
25 the average travel time by car to the nearest conventional static vaccine site, the cumulative number
26 of first dose administered at the start of the pre-intervention period, and the number of new first dose
27 vaccinations administered per week (Appendix 3 compares these measures between the intervention
28 and the rest of Cheshire and Merseyside).

29 We apply the synthetic control method for microdata developed by Robbins et al. to estimate the
30 effect of mobile vaccination units on vaccine uptake. Our outcome variable, weekly vaccine uptake, is
31 the percentage of adults who have received the first dose of the COVID-19 vaccine during each week
32 among the total eligible adult population.[30,31] The synthetic control method is a generalisation of
33 difference-in-difference methods.[32] An untreated version of the intervention areas (i.e. a synthetic

1 control) is created using a weighted combination of areas that were unexposed to the intervention.
2
3
4
5 1 The intervention effect is estimated by comparing the trend in outcomes in the intervention areas to
6
7 2 that in the synthetic control areas following the intervention.[33]

8
9 3 The weights were calculated using the raking method [34] so that the weighted averages for all the
10
11 4 variables outlined above in the synthetic control group were the same as for the intervention. This
12
13 5 included the cumulative number of first vaccine doses administered prior to the pre-intervention
14
15 6 period, the number of first dose vaccines administered in each of the seven weeks prior to the
16
17 7 intervention (Appendix 4) and each local area characteristic, outlined above.[30] Appendix 5 presents
18
19 8 the geographical distribution of these weights and illustrates how the synthetic control group is
20
21 9 constructed. The estimated effect of the mobile vaccination unit on the weekly number of first doses,
22
23 10 was calculated as the difference between the intervention and the (weighted) synthetic control
24
25 11 cohorts in the weekly number of vaccines received over a three-week period after the intervention.
26
27 12 To estimate the sampling distribution of the treatment effect, and the permuted p-values and 95%
28
29 13 confidence intervals, we applied a permutation procedure outlined by Robbins et al. by repeating the
30
31 14 analysis through 250 placebo permutations randomly allocating non-intervention LSOAs to the
32
33 15 intervention group.[31]

34
35 16 As our area-based analysis could be biased by insufficiently accounting for confounders at the
36
37 17 individual level, we additionally conducted analysis using individual-level data on all adults registered
38
39 18 with the GP and living in the intervention and non-intervention LSOAs (as defined above), who had
40
41 19 been unvaccinated before the mobile vaccination unit first visited their neighbourhood. We used a
42
43 20 weighted Poisson regression model with robust sandwich variance estimators, which has been shown
44
45 21 to be a valid alternative to the logistic regression model for the analysis of binary outcomes,[35,36] to
46
47 22 estimate the relative risk of vaccination by comparing the vaccine rates between these two groups in
48
49 23 the three weeks following the intervention. Using a weighted Poisson regression model to estimate
50
51 24 this effect without considering the differences between the intervention and non-intervention areas
52
53 25 on the aggregate level would potentially underestimate standard errors and p-values, as this would
54
55 26 not account for complex aspects of the process used to generate the synthetic control weights for
56
57 27 LSOAs. We therefore weighted this regression using the synthetic control weights as highlighted above
58
59 28 to account for systematic LSOA-level differences, after additionally controlling for the following
60
61 29 individual-level potential confounders: age, sex, ethnicity, health conditions (as defined above),
62
63 30 whether people were in contact with social care, whether they were paid carers and the travel time
64
65 31 by car from each person's address to the nearest conventional static vaccination centre. 18.62% and
66
67 32 0.01% of ethnicity and sex were missing respectively, leaving 233278 records for the main complete
68
69 33 case analysis.
70
71 34

1
2
3 1 To explore whether the mobile vaccination unit effect differed by deprivation, ethnicity, and age, we
4 fitted another weighted Poisson model including interaction terms between the intervention indicator
5 (mobile vaccination unit) and IMD tercile within Cheshire and Merseyside, ethnic group, and age group
6 respectively (see Appendix 6 and 7 for detailed results). Apart from the sensitivity test of excluding
7 ethnicity (Appendix 8) and the two pop-up sites (Appendix 9) from the analysis to assess the potential
8 impact of the missing data and two pop-up static sites on our results respectively, we have additionally
9 conducted a series of sensitivity tests on the dose effect of distance threshold used to construct the
10 intervention and non-intervention areas (Appendix 10), the potential spatial spill-over effect of the
11 intervention (Appendix 11), and survival analyses (Appendix 12) to further check the robustness of our
12 results.

13 **Patient and public involvement**

14 The local authorities delivering the intervention engaged with various community groups in promoting
15 the intervention and identifying intervention sites. Patients and the public were, however, not directly
16 involved in designing this analysis.

17 **Results**

18 Figure 1 shows the intervention (yellow) and the non-intervention areas (purple). The red and cyan
19 dots represent the mobile and pop-up static vaccination sites respectively. The map in Appendix 5
20 shows the weights that were applied to the non-intervention areas to construct the synthetic control.

21 **Figure 1 is about here**

22 Table 1 presents summary statistics for the intervention and non-intervention areas (see Appendix 3
23 for the comparison between the intervention and the rest of Cheshire and Merseyside). The average
24 vaccination rate of the first dose was much higher in the non-intervention areas before the
25 introduction of the intervention. On average, residents of the non-intervention areas had to travel
26 slightly longer to get to the nearest conventional static vaccine site. The intervention areas were
27 younger and more deprived, and had a higher proportion of overcrowded households, higher
28 proportions of Asian/Asian British and Black/Black British ethnic minority groups, and higher
29 population density. There were no differences in terms of the proportion of mixed ethnicity. As the
30 matching algorithm achieved an exact match, the *weighted* average of each variable in Table 1 was
31 identical in the synthetic control to those in the intervention areas.

Table 1. The summary statistics for the intervention and non-intervention areas at the intervention onset in the 7 weeks prior to the introduction of the mobile vaccination unit.

	Non-intervention areas	Intervention areas
Total population	1495582	338006
% women	50.84	48.92
Population density – people per hectare	38.84	65.11
Mean age	42.71	38.03
% Asian/Asian British	1.10	3.28
% Black/Black British	0.52	2.37
% Mixed people	1.48	1.87
IMD score¹	28.71	40.38
% households with at least one-bedroom fewer than they need	2.69	4.77
Average travel time by car to the nearest conventional static vaccine site - minutes	4.14	2.83
First dose vaccine uptake among adults (the percentage of adults who have received the first dose of COVID-19 vaccine among the total eligible adult population prior to pre-intervention) (%)	69.28	52.65
Average weekly first dose vaccination rate among adults in the 7 weeks prior to intervention (%)	1.85	1.51
Number of LSOAs	1112	216

Note¹: We primarily used the IMD score in our main model 1 and 2 in the following analysis. We then sorted the IMD score in ascending order and divided it into three equal parts to facilitate our subgroup analysis by level of deprivation.

Figure 2 shows the trend in weekly vaccination rate in the intervention and synthetic control areas, during a 11-week period (seven weeks before and three weeks after the introduction of the mobile vaccination unit). For the pre-intervention period, trends were indistinguishable, as the synthetic control algorithm has achieved an exact match by successfully calibrating the weights. From the time point of the intervention being introduced, weekly vaccination rates increased from 1.5% to 1.9% in the intervention areas. Trends in the matched synthetic control areas that were not visited by a mobile vaccination unit remained fairly flat, with a small decrease in the post-intervention period. From two weeks post intervention, 95% CIs stopped overlapping.

Figure 2 is about here

Table 2 shows the estimated effect of the mobile vaccination units on weekly vaccination rate, the percentage of adults who have received the first dose of the COVID-19 vaccine in each week among the total eligible adult population, using two models based on area-level and individual-level data respectively. The two analyses show similar results. The area-based analysis indicates that vaccination rates in the neighbourhoods visited by mobile vaccination units were 23% higher in the three weeks

1 after the first visit, compared to what would have been the case without the mobile vaccination units'
 2 visits (RR = 1.23, 95% CI: 1.11 to 1.36). The relative risks adjusted for individual-level characteristics is
 3 slightly higher than that of the area-based model (RR = 1.25, 95% CI: 1.21 to 1.28). This overall effect
 4 size estimates 3723 additional vaccinations over three weeks of follow-up across the study area,
 5 similar to the actual number of people vaccinated in the mobile units (n=3824). Sensitivity tests
 6 excluding ethnicity and the two pop-up sites showed similar results with those of model 2 (see
 7 Appendix 8 and 9 respectively). Whilst sensitivity tests on the distance threshold demonstrated the
 8 spatially sensitive nature of our analysis (Appendix 10), our results are relatively robust against the
 9 spatial spill-over effect once an appropriate distance threshold was chosen (Appendix 11).

10 **Table 2. Estimated effect of mobile vaccination units on weekly vaccination rate (the percentage of**
 11 **adults who have received the first dose of the COVID-19 vaccine in each week among the total**
 12 **eligible adult population), the table shows the relative risks indicating the estimated ratio of vaccine**
 13 **rates in the intervention group compared to the synthetic control group in the 3 weeks following**
 14 **intervention. Model 1 uses LSOA level data, accounting for area-based differences between**
 15 **intervention and non-intervention areas, with permuted p-values and confidence intervals. Whilst**
 16 **model 2 additionally controls for individual differences between intervention and non-intervention**
 17 **groups.**

	RR	95% CI		p-value
		LCL	UCL	
Model 1. LSOA level synthetic control analysis	1.23	1.11	1.36	<0.001
Model 2. Individual level weighted Poisson regression analysis	1.25	1.21	1.28	<0.001

41 Note: RR is relative risk. CI refers to confidence interval. LCL and UCL are the lower and upper confidence
 42 interval respectively.

18 We used interaction analyses to investigate if the intervention effect was modified by deprivation,
 19 ethnicity, and age (see Appendix 6). We found a significant interaction between deprivation and the
 20 intervention indicating reduced effectiveness with increased deprivation ($p < 0.001$), a significant
 21 interaction with ethnicity indicating reduced effectiveness for Asian/Asian British ($p = 0.006$),
 22 Black/Black British ($p = 0.005$) or other ethnic groups ($p = 0.010$), compared to White/White British
 23 people, and a significant interaction with age indicating reduced effectiveness in older age groups. The
 24 combination of these interaction effects means that in many groups defined by age, ethnicity, and
 25 deprivation there was no evidence of effectiveness (see Figure 3).

26 **Figure 3 is about here**

1
2
3 1 Figure 3 shows estimated effect of mobile vaccination units on weekly vaccine uptake for all the
4 2 subgroups using the combination of the effect in the reference group (18–30-year-olds of white
5 3 ethnicity living in the least deprived neighbourhoods that were visited by the mobile vaccination unit)
6 4 and the interaction terms for deprivation, ethnicity, and age group. The relative effect of the
7 5 intervention for the reference group is shown in the bottom left cell of Figure 3, indicating that the
8 6 intervention increased vaccine uptake by 68% (RR 1.68) for 18–30-year-olds of white ethnicity living
9 7 in the least deprived neighbourhoods and having received the intervention relative to people of the
10 8 same age group, ethnicity, living in neighbourhoods of the same deprivation level but without the
11 9 intervention. For people of same ethnic and age group but living in intermediately deprived areas, the
12 10 effect was slightly larger (RR 1.82, 82% increase; calculated as the combination of the effect on the
13 11 reference group and the interaction term for intermediate deprivation with mobile vaccination units:
14 12 $1.683 \times 1.081 = 1.82$; see Appendix 6), whilst for those living in the most deprived areas it was lower (RR
15 13 1.30, 30% increase; calculated as 1.683×0.770 in the same manner as above). Effects of other
16 14 subgroups could be interpreted in the same way. Due to the small sample sizes of these 45 subgroups
17 15 (see Appendix 7), these results should be treated with caution. However, they indicate the likely
18 16 pattern of effects of the intervention across these groups. Overall, White, 18–30-year-olds living in
19 17 neighbourhoods of intermediated deprivation appeared to benefit the most from visits of the mobile
20 18 vaccination unit (Figure 3). Effects were lowest for older age groups in the most deprived areas.
21 19 Although the effect of the mobile vaccination unit may be lower for the most deprived population and
22 20 for people from Black, Asian, and other ethnic minority groups, the mobile vaccination unit does still
23 21 appear to have increased uptake in these groups for younger people, whilst we find no evidence of a
24 22 positive effect for most older age groups from Black, Asian, and other ethnic minority groups,
25 23 particularly in deprived areas. The survival analysis showed similar results overall (Appendix 12).

24 Discussion

25 Our study presents much-needed empirical evidence of the effectiveness of mobile vaccination units
26 26 in promoting COVID-19 vaccination, indicating that they can increase uptake in their targeted
27 27 neighbourhoods. The effect size estimated in our analysis closely corresponds to the actual number,
28 28 indicating that a significant proportion of vaccinations conducted in the mobile units were additional.
29 29 Put simply, our findings suggest that among individuals utilising the mobile vaccination units, there
30 30 was a minimal number who would have otherwise sought their vaccinations at conventional static
31 31 centres. This implies that the mobile vaccination units effectively reached individuals who may have
32 32 faced barriers in accessing conventional static vaccination sites. Our study therefore also lends support
33 33 to previous studies on other forms of preventative care that mobile units are useful tools in improving
34 34 geographical accessibility and convenience of services for patients.[12–15]

1
2
3 1 Within those neighbourhoods, however, the intervention tended to increase uptake most amongst
4 2 younger people, white people and less socioeconomically deprived areas. However, the targeted
5 3 neighbourhoods were the most deprived. Our analysis indicated that the intervention was similarly
6 4 effective in the least deprived and intermediate levels of deprivation *within* these targeted
7 5 neighbourhoods. It is only in areas with IMD score of over 53, the lower bound of the most deprived,
8 6 that the effectiveness declined. However, 53 is at the 95th percentile of the national distribution of
9 7 IMD scores, representing very deprived areas nationwide. Our findings indicate therefore that the
10 8 intervention was effective at increasing uptake amongst young people in relatively deprived areas
11 9 (although not in extremely deprived areas) and across young people from all ethnic groups in these
12 10 areas.

13 11 Our study has limitations. We only had data on individuals who had been registered with the GP at
14 12 time of our study. The GP registered population is larger than that of the 2021 Census (2.7 million vs.
15 13 2.5 million people) due to known data issues (e.g., delays in people updating addresses when move
16 14 home, different definitions of resident population). Although unregistered people attending for
17 15 mobile units were encouraged and can register with a GP in their attendance, there may have been
18 16 people vaccinated who did not wish to be registered, such as undocumented immigrants, homeless
19 17 populations, travellers, and displaced people. We were unable to estimate the impact of the
20 18 intervention in these groups. The mobile vaccination unit could have increased uptake due to
21 19 improved accessibility through the mobile vaccination unit itself and/or the awareness raising and
22 20 publicity associated with visits of these units. Our analysis cannot distinguish between these effects.

23 21 Our analysis covers a relatively short period of follow-up. We are therefore unable to determine
24 22 whether the observed effect is due to people being vaccinated earlier than they would otherwise have
25 23 been or if they would have never taken up vaccine without the intervention. We could link
26 24 approximate but not exact time/date visits of the mobile units. Further research should look to
27 25 evaluate if mobile units had different effects at different stages of a pandemic (e.g., initial roll out
28 26 compared to re-opening of society or once most people have been vaccinated by traditional means).
29 27 We used a measure of average distance to construct the intervention and non-intervention group,
30 28 which would have made our effect estimate more conservative (see Appendix 11) and more sensitive
31 29 to the choice of threshold (Appendix 10). Selecting an appropriate distance threshold is difficult,
32 30 suggesting the need to evaluate how distance might impact the delivery and impact of mobile
33 31 interventions. This not only reflects the geographical nature of the intervention but indicates the
34 32 potential benefit of improving the data quality for the distance measurement in future research.
35 33 Although we have accounted for observed differences between places visited by the mobile
36 34
37 35
38 36
39 37
40 38
41 39
42 40
43 41
44 42
45 43
46 44
47 45
48 46
49 47
50 48
51 49
52 50
53 51
54 52
55 53
56 54
57 55
58 56
59 57
60 58

1
2
3 1 vaccination units and those not and differences in individual characteristics, it is still possible that
4
5 2 unmeasured confounding could bias the results.
6

7 3 **Conclusion**

8
9 4 Our study has implications for strategies aiming to increase vaccine uptake. By improving geographic
10
11 5 accessibility and convenience of services, the mobile vaccination unit likely promoted uptake of the
12
13 6 first dose of the COVID-19 vaccine in our study population. The evidence indicating greater effects in
14
15 7 less deprived areas and in the White/White British population raises concerns that the intervention
16
17 8 could however lead to an increase in inequalities in uptake within targeted areas. It is important to
18
19 9 ensure the mobile vaccination units are effectively targeted to the communities with low uptake and
20
21 10 combined with comprehensive engagement and outreach with Black and Asian ethnic groups and with
22
23 11 more socioeconomically disadvantaged communities. With successive SARS-CoV-2 variants and the
24
25 12 need for multiple vaccine doses to achieve sufficient immunity, rapidly increasing uptake and reducing
26
27 13 inequalities in uptake was of critical public health importance. Deployment of mobile units alongside
28
29 14 other effective approaches to increase uptake in disadvantaged groups can contribute to this goal.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Transparency statement**

2 The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of
3 the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the
4 study as originally planned (and, if relevant, registered) have been explained.
5

6 **Author contribution statement**

7 B.B. conceived the original idea, devised the project, the main conceptual ideas and proof outline. X.Z. contributed to the
8 literature review, collected the data, and carried out the data analysis. R.A. conducted the initial literature review. X.Z.
9 drafted the manuscript and designed the figures with support from B.B. and M.G.. J.T., S.K. and P.P. assisted with the data
10 access and commented on the manuscript. R.P. assisted in coding. M.GF and M.G. aided in commenting on the manuscript.
11 I.B. aided in supervising the project and commented on the manuscript. S.B. helped to improve the language and
12 visualisation. All authors provided critical feedback and helped to shape the research manuscript.
13

14 **Conflicts of interest statement**

15 We have no conflicts of interest to disclose.
16

17 **Ethics statements**

18 Patient consent for publication

19 Not required.
20

21 **Ethics approval**

22 University Research Ethics Committee review is not required by the University of Liverpool for the secondary analysis of data
23 which have been anonymised by an external party and are provided to the research team in a fully anonymised format.
24

25 **Data sharing statement**

26 The individual-level data is sensitive and could not be shared. But statistical codes are available from
27 <https://github.com/civcdatacoop/mobileVaxUnit>.
28

29 **Funding**

30 This research was funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in
31 Gastrointestinal Infections (ref NIHR200910), the NIHR Policy Research Programme (RESTORE; Award ID, NIHR202484), the
32 NIHR Applied Research Collaboration Northwest Coast (NWC ARC), and The Pandemic Institute (formed of seven founding
33 partners: The University of Liverpool, Liverpool School of Tropical Medicine, Liverpool John Moores University, Liverpool City
34 Council, Liverpool City Region Combined Authority, Liverpool University Hospital Foundation Trust, and Knowledge Quarter
35 Liverpool). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of
36 Health and Social Care, Public Health England, or The Pandemic Institute.
37

1
2
3 **1 References**
4

- 5 2 1 WHO | Vaccination greatly reduces disease, disability, death and inequity worldwide. WHO.
6 3 <https://www.who.int/bulletin/volumes/86/2/07-040089/en/> (accessed 3 Jun 2021).
7
- 8 4 2 Baraniuk C. Covid-19: How the UK vaccine rollout delivered success, so far. *BMJ* 2021;**372**:n421.
9 5 doi:10.1136/bmj.n421
- 10 6 3 Campos-Matos I, Mandal S, Yates J, *et al.* Maximising benefit, reducing inequalities and ensuring
11 7 deliverability: Prioritisation of COVID-19 vaccination in the UK. *Lancet Reg Health-Eur* 2021;**2**.
12
- 13 8 4 Razai MS, Osama T, McKechnie DG, *et al.* Covid-19 vaccine hesitancy among ethnic minority
14 9 groups. British Medical Journal Publishing Group 2021.
- 15 10 5 Osama T, Razai MS, Majeed A. COVID-19 vaccine allocation: addressing the United Kingdom's
16 11 colour-blind strategy. *J R Soc Med* 2021;:01410768211001581.
- 17 12 6 Collaborative TO, MacKenna B, Curtis HJ, *et al.* Trends, regional variation, and clinical
18 13 characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million
19 14 patients using OpenSAFELY. *medRxiv* 2021;:2021.01.25.21250356.
20 15 doi:10.1101/2021.01.25.21250356
- 21 16 7 Vaccine Coverage - Third/Booster Doses | OpenSAFELY: Reports.
22 17 <http://reports.opensafely.org/reports/vaccine-coverage-thirdbooster-doses/> (accessed 21 Dec
23 18 2021).
- 24 19 8 £22.5m of funding announced in new community push to get nation boosted now. GOV.UK.
25 20 [https://www.gov.uk/government/news/225m-of-funding-announced-in-new-community-push-](https://www.gov.uk/government/news/225m-of-funding-announced-in-new-community-push-to-get-nation-boosted-now)
26 21 [to-get-nation-boosted-now](https://www.gov.uk/government/news/225m-of-funding-announced-in-new-community-push-to-get-nation-boosted-now) (accessed 20 Dec 2021).
27
- 28 22 9 Final report on progress to address COVID-19 health inequalities. GOV.UK.
29 23 [https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-](https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-health-inequalities/final-report-on-progress-to-address-covid-19-health-inequalities)
30 24 [health-inequalities/final-report-on-progress-to-address-covid-19-health-inequalities](https://www.gov.uk/government/publications/final-report-on-progress-to-address-covid-19-health-inequalities/final-report-on-progress-to-address-covid-19-health-inequalities) (accessed
31 25 21 Dec 2021).
32
- 33 26 10 ECDC. Facilitating vaccination acceptance and uptake in the EU/EEA. Stockholm: : ECDC 2021.
34 27 [https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-](https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-acceptance-and-uptake)
35 28 [acceptance-and-uptake](https://www.ecdc.europa.eu/en/publications-data/facilitating-covid-19-vaccination-acceptance-and-uptake)
- 36 29 11 Armocida B, Formenti B, Missoni E, *et al.* Challenges in the equitable access to COVID-19
37 30 vaccines for migrant populations in Europe. *Lancet Reg Health – Eur* 2021;**6**.
38 31 doi:10.1016/j.lanepe.2021.100147
- 39 32 12 Williams EM, Vessey MP. Randomised trial of two strategies offering women mobile screening
40 33 for breast cancer. *BMJ* 1989;**299**:158–9.
- 41 34 13 Greenwald ZR, El-Zein M, Bouten S, *et al.* Mobile Screening Units for the Early Detection of
42 35 Cancer: A Systematic Review. *Cancer Epidemiol Biomarkers Prev* 2017;**26**:1679–94.
43 36 doi:10.1158/1055-9965.EPI-17-0454
- 44 37 14 Reuben DB, Bassett LW, Hirsch SH, *et al.* A Randomized Clinical Trial to Assess the Benefit of
45 38 Offering On-Site Mobile Mammography in Addition to Health Education for Older Women. *Am J*
46 39 *Roentgenol* 2002;**179**:1509–14. doi:10.2214/ajr.179.6.1791509

- 1
2
3 1 15 Shima A, Tanaka H, Okamura T, *et al.* Offering on-site mammography in workplaces improved
4 2 screening rates: Cluster randomized controlled trial. *J Occup Health* 2023;**65**:e12389.
5 3 doi:10.1002/1348-9585.12389
6
7 4 16 Freeman D, Loe BS, Yu L-M, *et al.* Effects of different types of written vaccination information on
8 5 COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised
9 6 controlled trial. *Lancet Public Health* 2021;**0**. doi:10/gk725x
10
11 7 17 Dai H, Saccardo S, Han MA, *et al.* Behavioural nudges increase COVID-19 vaccinations. *Nature*
12 8 2021;**597**:404–9. doi:10/gqtk
13
14 9 18 Marquez C, Kerkhoff AD, Naso J, *et al.* A multi-component, community-based strategy to
15 10 facilitate COVID-19 vaccine uptake among Latinx populations: From theory to practice. *PLOS*
16 11 *ONE* 2021;**16**:e0257111. doi:10/gn2bbs
17
18 12 19 Gupta PS, Mohareb AM, Valdes C, *et al.* Expanding COVID-19 vaccine access to underserved
19 13 populations through implementation of mobile vaccination units. *Prev Med* 2022;**163**:107226.
20 14 doi:10.1016/j.ypmed.2022.107226
21
22 15 20 Ecartot F, Maggi S, Michel J-P. Strategies to improve vaccine uptake throughout adulthood.
23 16 *Vaccines Older Adults Curr Pract Future Oppor* 2020;**43**:234–48.
24
25 17 21 Arthur AJ, Matthews RJ, Jagger C, *et al.* Improving uptake of influenza vaccination among older
26 18 people: a randomised controlled trial. *Br J Gen Pract* 2002;**52**:717–22.
27
28 19 22 Hull S, Hagdrup N, Hart B, *et al.* Boosting uptake of influenza immunisation: a randomised
29 20 controlled trial of telephone appointing in general practice. *Br J Gen Pract* 2002;**52**:712–6.
30
31 21 23 Humiston SG, Bennett NM, Long C, *et al.* Increasing inner-city adult influenza vaccination rates: a
32 22 randomized controlled trial. *Public Health Rep* 2011;**126**:39–47.
33
34 23 24 Krieger JW, Castorina JS, Walls ML, *et al.* Increasing influenza and pneumococcal immunization
35 24 rates: a randomized controlled study of a senior center–based intervention. *Am J Prev Med*
36 25 2000;**18**:123–31.
37
38 26 25 Leung KC, Mui C, Chiu WY, *et al.* Impact of patient education on influenza vaccine uptake among
39 27 community-dwelling elderly: a randomized controlled trial. *Health Educ Res* 2017;**32**:455–64.
40
41 28 26 Siriwardena AN, Rashid A, Johnson MR, *et al.* Cluster randomised controlled trial of an
42 29 educational outreach visit to improve influenza and pneumococcal immunisation rates in
43 30 primary care. *Br J Gen Pract* 2002;**52**:735–40.
44
45 31 27 Chan SS, Leung DY, Leung AY, *et al.* A nurse-delivered brief health education intervention to
46 32 improve pneumococcal vaccination rate among older patients with chronic diseases: a cluster
47 33 randomized controlled trial. *Int J Nurs Stud* 2015;**52**:317–24.
48
49 34 28 CIPHA -. <https://www.cipha.nhs.uk/> (accessed 21 Dec 2021).
50
51 35 29 Best J. How the JCVI sets who gets a covid-19 vaccine and when. *BMJ* 2021;**373**:n820.
52 36 doi:10/gpv8m2
53
54
55
56
57
58
59
60

- 1
2
3 1 30 Robbins MW, Davenport S. microsynth: Synthetic Control Methods for Disaggregated and Micro-
4 2 Level Data in R. *J Stat Softw Vol 1 Issue 2 2021* Published Online First: 14 January
5 3 2021. <https://www.jstatsoft.org/v097/i02>
6
7 4 31 Robbins MW, Saunders J, Kilmer B. A Framework for Synthetic Control Methods With High-
8 5 Dimensional, Micro-Level Data: Evaluating a Neighborhood-Specific Crime Intervention. *J Am*
9 6 *Stat Assoc* 2017;**112**:109–26. doi:10/f9746k
11
12 7 32 Barr B, Zhang X, Green M, *et al.* A blueprint for synthetic control methodology: a causal
13 8 inference tool for evaluating natural experiments in population health. *bmj* 2022;**379**.
14
15 9 33 Zhang X, Owen G, Green M, *et al.* Evaluating the Impacts of Tiered Restrictions Introduced in
16 10 England, During October and December 2020 on COVID-19 Cases: A Synthetic Control Study.
17 11 Rochester, NY: : Social Science Research Network 2021. doi:10.2139/ssrn.3805859
18
19 12 34 Raking. In: *Encyclopedia of Survey Research Methods*. 2455 Teller Road, Thousand
20 13 Oaks California 91320 United States of America: : Sage Publications, Inc. 2008.
21 14 doi:10.4135/9781412963947.n433
22
23 15 35 Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. *Am J*
24 16 *Epidemiol* 2004;**159**:702–6. doi:10/cjn5zq
25
26 17 36 Greenland S. Model-based estimation of relative risks and other epidemiologic measures in
27 18 studies of common outcomes and in case-control studies. *Am J Epidemiol* 2004;**160**:301–5.
28 19 doi:10/c6nd87
29
30
31 20
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1. Location of the 35 eligible mobile vaccination units (red dots), the two static pop-up sites**
4 **(cyan dots), and the non-intervention (purple) and intervention (yellow) areas across Cheshire and**
5 **Merseyside. The sub-map in the box of the top right shows the location of Cheshire and**
6 **Merseyside in England.**
7
8
9

10 **Figure 2. The trend in the weekly vaccination rate with their 95% confidence intervals in the**
11 **intervention and synthetic control areas.**
12
13

14
15 **Figure 3. Heatmap of the estimated impact of the mobile vaccination units upon weekly number of**
16 **first dose COVID-19 vaccines administered among all the subgroups based on interaction analysis.**
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Location of the 35 eligible mobile vaccination units (red dots), the two static pop-up sites (cyan dots), and the non-intervention (purple) and intervention (yellow) areas across Cheshire and Merseyside. The sub-map in the box of the top right shows the location of Cheshire and Merseyside in England

2257x1975mm (72 x 72 DPI)




Figure 2. The trend in the weekly vaccination rate with their 95% confidence intervals in the intervention and synthetic control areas.

2257x1975mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Heatmap of the estimated impact of the mobile vaccination units upon weekly number of first dose COVID-19 vaccines administered among all the subgroups based on interaction analysis.

2257x1975mm (72 x 72 DPI)

Appendices

Appendix 1. Timeline of the age eligibility for the rollout of the COVID-19 vaccine programme for the first dose in England.

Table A1. The availability of vaccine appointments for the first dose of COVID-19 vaccine in England, by date.

Start date	Appointments available for
8 December 2020	Residents in a care home for older adults and their carers; and all aged 80 and over
Procedures set out on 9 and 14 January 2021	Frontline health and social care workers
18 January 2021	All aged 70 and over, and clinically extremely vulnerable individuals
15 February 2021	All aged 65 and over; and those aged 16 to 64 with underlying health conditions which put them at higher risk of serious disease and mortality
1 March 2021	All aged 60 and over
6 March 2021	All aged 56 and over
17 March 2021	All aged 50 and over
13 April 2021	All aged 45 and over
26 April 2021	All aged 44 and over
27 April 2021	All aged 42 and over
30 April 2021	All aged 40 and over
13 May 2021	All aged 38 and over
18 May 2021	All aged 36 and over
20 May 2021	All aged 34 and over
22 May 2021	All aged 32 and over
26 May 2021	All aged 30 and over
8 June 2021	All aged 25 and over
15 June 2021	All aged 23 and over
16 June 2021	All aged 21 and over
18 June 2021	All adults (namely aged 18 and over)

Source: [COVID-19 vaccination in the United Kingdom - Wikipedia](#).

Appendix 2. Crude and age-adjusted accumulated uptake of the COVID-19 vaccine first dose in Cheshire and Merseyside between the 49th week of 2020 (6th to 12th December 2020; the first COVID-19 vaccine was administered in the UK on 8th December 2020) and the 29th week of 2021 (18th to 24th July 2021; the end point of our study is 19th July 2021, three weeks after the last mobile vaccination unit visit on 28th June 2021).




Figure A1. Crude accumulated uptake rate of the first dose COVID-19 vaccine across Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021, the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). After a relatively linear and stable growth between the 1st and 7th week of 2021, Cheshire and Merseyside started to see signs of slowing down in the crude uptake rate since the 8th week of 2021 (21st to 27th February 2021).







Figure A2. Average crude accumulated uptake rate of the first dose COVID-19 vaccine across all lower layer super-output areas (LSOAs) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021, with its 95% confidence intervals. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), LSOAs of Cheshire and Merseyside had seen expanding variations in their crude accumulated uptake of the first dose COVID-19 vaccine.




A3. Crude accumulated uptake rate of the first dose COVID-19 vaccine among ethnic groups (White, Asian or Asian British, Black or Black British, Mixed, and Other) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), ethnic groups of Cheshire and Merseyside had seen widening gaps in their crude accumulated uptake of the first dose COVID-19 vaccine.



A4. Age-adjusted accumulated uptake rate of the first dose COVID-19 vaccine among ethnic groups (White, Asian or Asian British, Black or Black British, Mixed, and Other) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). The 8th week of 2021 (21st to 27th February 2021), as a turning point, had become pronounced for widening gaps in age-adjusted accumulated uptake of the first dose COVID-19 vaccine among ethnic groups in Cheshire and Merseyside.



A5. Crude accumulated uptake rate of the first dose COVID-19 vaccine among different socio-economic groups (Least deprived, Intermediate deprivation, and Most deprived) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), different socio-economic groups of Cheshire and Merseyside had seen increasingly growing gaps in their crude accumulated uptake of the first dose COVID-19 vaccine.



A6. Age-adjusted accumulated uptake rate of the first dose COVID-19 vaccine among different socio-economic groups (Least deprived, Intermediate deprivation, and Most deprived) in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021 (within the 8th week of 2021), the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021). Since the 8th week of 2021 (21st to 27th February 2021), different socio-economic groups of Cheshire and Merseyside had seen signs of widening gaps in their age-adjusted accumulated uptake of the first dose COVID-19 vaccine.




Figure A7. Crude accumulated uptake rate of the first dose COVID-19 vaccine by local authorities in Cheshire and Merseyside between the 49th week of 2020 and the 29th week of 2021. The dashed red vertical line represented the date of 22nd February 2021, the starting point of our study (seven weeks before the first mobile vaccination unit visit on 12th April 2021).

Appendix 3. Summary statistics of the intervention and full non-intervention population at the intervention onset in the 7 weeks prior to the introduction of the mobile vaccination unit.

Whilst Table 1 presents summary statistics for the intervention and non-intervention areas within the eight local authorities that reported data on the deployment (or non-deployment) of the mobile vaccination units and therefore are used to conduct the main analysis, Table A2 below shows the comparison between the intervention and the rest of the Cheshire and Merseyside, including the eight local authorities above and the one local authority with missing data on the intervention that has been excluded from the main analysis.

Table A2. The comparison between the intervention and the rest of Cheshire and Merseyside at the intervention onset in the 7 weeks prior to the introduction of the mobile vaccination unit.

	Rest of the Cheshire and Merseyside region	Intervention areas
Total population	1829809	338006
% women	50.72	48.92
Population density – people per hectare	34.88	65.11
Mean age	42.72	38.03
% Asian/Asian British	1.20	3.28
% Black/Black British	0.52	2.37
% Mixed people	1.39	1.87
IMD score	25.83	40.38
% households with at least one-bedroom fewer than they need	2.55	4.77
Average travel time by car to the nearest conventional static vaccine site - minutes	4.28	2.83
First dose vaccine uptake among adults (the percentage of adults who have received the first dose of COVID-19 vaccine among the total eligible adult population prior to pre-intervention) (%)	66.15	52.65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Average weekly first dose vaccination rate among adults in the 7 weeks prior to intervention (%)	2.08	1.51
Number of LSOAs	1346	216

For peer review only

Appendix 4. The weekly number of the first dose administered in the intervention and control groups for each of the seven weeks prior to the intervention (the mobile vaccination unit).

Table A3. Weekly number of the first dose administered in the intervention and control groups for each of the seven weeks prior to the intervention (the mobile vaccination unit).

Weeks before the intervention	Weekly number of the first dose administered in the LSOAs being visited by the mobile vaccination units	Weekly number of the first dose administered in the LSOAs in the rest of Cheshire & Merseyside used to construct the synthetic control	Weekly number of the first dose administered in the synthetic control (weighting LSOAs in the rest of Cheshire & Merseyside using synthetic control weights)
7	5692	31995	5692
6	5040	29288	5040
5	5256	31869	5256
4	5537	33022	5537
3	4730	24901	4730
2	4493	21180	4493
1	5059	21685	5059

Appendix 5. Geographical pattern of weights in area-based synthetic control analysis.




Figure A8. Weighting of areas outside of the catchment of the mobile vaccination units to construct the synthetic control group. Areas within the catchment of the mobile vaccination units are coloured black, whilst locations of the mobile vaccination unit are represented by red (35 mobile sites) and cyan (two static pop-up sites) dots. The white non-intervention areas are those that have been allocated zero weights in constructing the synthetic control, whilst other coloured non-intervention areas are those with non-zero weights in constructing the synthetic control: the darker the colour, the larger the weight.

Appendix 6. Regression output for the interaction model based on adult individuals.

Subgroup analysis by deprivation, ethnicity and age indicates, lower impact of the mobile vaccination unit on vaccination uptake for the most deprived areas compared to more affluent areas, a lower impact for Asian/Asian British, Black/Black British or Other ethnic groups, compared to white British people, and a lower impact on people aged 31-65-year-olds. The sample sizes are quite low for the subgroup analysis (see Appendix 7 below for more details) so the results reported here are only indicative of the overall pattern. Table A4 below shows the effect sizes of the mobile vaccination unit for the subgroups as relative risks. Compared to people not visited by the mobile vaccination units in their neighbourhoods, visits of the mobile vaccination units have increased vaccination rates in the following groups: people aged 18-30 from all socio-economic backgrounds and all ethnic groups except for Black/Black British; White/White British people aged above 30 from least and intermediate deprived areas; people aged 30-65 of mixed and other ethnic groups from the intermediate deprived areas; and people aged above 65 of mixed and other ethnic groups from least and intermediate deprived areas (see Figure 3 in the main text for more details).

Table A4. Regression output with interaction terms based on adult individuals. The table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention.


Variables	RR	95% CI		p-value
		LCL	UCL	
Mobile vaccination unit (reference: no mobile vaccination unit)	1.683	1.584	1.789	<0.001
Age group (reference: 18-30 years old)				
(30,65]	1.249	1.187	1.313	<0.001
65+	0.201	0.147	0.275	<0.001
Sex (reference: Women)				
Men	1.013	0.984	1.042	0.380
Ethnicity (reference: White/White British)				
Asian/Asian British	0.919	0.791	1.068	0.271
Black/Black British	0.749	0.605	0.929	0.008
Mixed	0.746	0.608	0.915	0.005
Other ethnic groups	0.799	0.746	0.856	<0.001
IMD tercile (reference: Least deprived)				
Intermediate deprivation	0.786	0.741	0.834	<0.001
Most deprived areas	0.673	0.631	0.718	<0.001
Chronic health conditions (reference: none)	1.098	1.076	1.120	<0.001
Carer (reference: not carer)	0.320	0.273	0.375	<0.001
Social care receiver (reference: not social care receiver)	0.979	0.764	1.255	0.869
Travel time by car to the nearest static vaccine centre (minutes)	1.087	1.082	1.093	<0.001
Interaction between age groups and mobile vaccination unit (reference: 18-30 years old with mobile vaccination unit)				
31-65 years old with mobile vaccination unit	0.638	0.602	0.676	<0.001
65+ years old with mobile vaccination unit	0.700	0.475	1.030	0.070
Interaction between ethnicity and mobile vaccination unit (reference: White/White British with mobile vaccination unit)				
Asian/Asian British with mobile vaccination unit	0.788	0.664	0.935	0.006
Black/Black British with mobile vaccination unit	0.704	0.550	0.901	0.005

Mixed with mobile vaccination unit	0.900	0.712	1.138	0.379
Other ethnic groups with mobile vaccination unit	0.903	0.835	0.976	0.010
Interaction between IMD tercile and mobile vaccination unit (reference: Least deprived with mobile vaccination unit)				
Intermediate deprivation with mobile vaccination unit	1.081	1.010	1.158	0.024
Most deprived areas with mobile vaccination unit	0.770	0.715	0.829	<0.001
Note: The intercept is excluded from the output. We reported the result in three decimal digits specifically here to facilitate the explanation on how to interpret interaction terms.				

For peer review only

Appendix 7. Sample size of the sub-groups (with visits of the mobile vaccination units) in the weighted Poisson model including interaction terms between the intervention indicator (mobile vaccination unit) and IMD tercile within Cheshire and Merseyside, ethnic and age groups respectively.

Figure A10. Heatmap of the sample size for each subgroup receiving the visit of the mobile vaccination units based on interaction analysis.



Appendix 8. Sensitivity test – excluding ethnicity from the main model.

Table A5. Results of analysis for adult individuals of all ages, excluding ethnicity.

	RR	95% CI		p-value
		LCL	UCL	
Model 2a. Individual level weighted Poisson regression analysis	1.24	1.21	1.28	<0.001

Results of individual-level analysis presented in Table A5 and Table 2 are almost identical, implying that excluding cases with missing information on ethnicity did not affect the robustness of our results.

Appendix 9. Sensitivity test – excluding the two pop-up sites across C&M.

Table A6. Results of analysis for adult individuals of all ages, excluding the two pop-up sites.

	RR	95% CI		p-value
		LCL	UCL	
Model 2b. Individual level weighted Poisson regression analysis	1.23	1.18	1.29	<0.001

Table A6 of individual-level analysis shows very similar results to those of Table 2, indicating that it is unlikely that the use of the two pop-up sites rather than vaccine buses alone influenced our results overall.

Appendix 10. Sensitivity test – results of the synthetic control method based on different distance thresholds in constructing the synthetic control.

Table A7. Estimated effect of mobile vaccination units on weekly vaccine uptake (the percentage of adults who have received the first dose of the COVID-19 vaccine in a given week among the total eligible adult population), the table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention. Model 1a uses the 500 meter distance threshold to construct the intervention and non-intervention areas with LSOA level data, accounting for area-based differences between intervention and non-intervention areas, with permuted p-values and confidence intervals. Model 1b, 1c and 1d use the distance threshold of 1, 2 and 3KM respectively, all else equal.

	RR	95% CI		p-value
		LCL	UCL	
Model 1a. LSOA level synthetic control analysis – 500-meter threshold	1.10	-1.04	1.30	0.208
Model 1b. LSOA level synthetic control analysis – 1500-meter threshold	1.15	1.04	1.26	<0.001
Model 1c. LSOA level synthetic control analysis – 2000-meter threshold	1.05	-1.04	1.17	0.280
Model 1d. LSOA level synthetic control analysis – 3000-meter threshold	1.02	-1.12	1.19	0.888

Note: RR is relative risk. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

Appendix 11. Sensitivity test – results of the synthetic control method excluding LSOAs with centroids located between 1 to 1.5 km from the nearest mobile vaccination unit to account for the potential spatial spill over effect.

Table A8. Estimated effect of mobile vaccination units on weekly vaccine uptake (the percentage of adults who have received the first dose of the COVID-19 vaccine in a given week among the total eligible adult population), the table shows the relative risks indicating the estimated ratio of vaccine rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention. Model 1e uses the same distance threshold (1 km) as the main model 1 to construct the intervention and non-intervention areas with LSOA level data, but excludes LSOAs with population weighted centroids located between 1 and 1.5km from the nearest mobile vaccination unit to additionally account for the potential spatial spill over effect, with permuted p-values and confidence intervals.

	RR	95% CI		p-value
		LCL	UCL	
Model 1e. LSOA level synthetic control analysis – accounting for potential spatial spill over effect between 1 and 1.5 km	1.24	1.11	1.40	<0.001

Note: RR is relative risk. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

Appendix 12. Sensitivity test – results of survival analyses based on adult individuals.

Using weights calibrated in the synthetic control analysis, we conducted a survival analysis to check the robustness of the synthetic control analysis. In this analysis, we compared the survival probability (the probability of adults to stay unvaccinated) between the synthetic control and intervention groups in the three weeks following the intervention, only including unvaccinated adults at the time of the intervention, a binary categorical variable indicating whether an individual had received the first-dose of the COVID-19 vaccine as the outcome variable, the number of week from the intervention as the time variable, and the variable of the intervention (the mobile bus units). Figure A8 below shows the survival curves of two groups and the risk table. Even without controlling for any individual-level confounders used in the main individual-level analysis, this model estimates 3487 additional vaccinations over three weeks of follow-up period ($3487 = (32005 - 47132) - (29878 - 48492)$), broadly in line with the effect size estimated in the main analysis ($n=3723$).




Figure A9. The survival curves of the synthetic control (coloured in purple) and intervention groups (coloured in yellow) with their respective 95% confidence intervals and the risk table, following the same colouring scheme of Figure 2 in the main analysis.

We then used a Cox proportional hazards regression model to replicate the sub-group analysis in Appendix 6. Results are shown in Table A9, similar to Table A4 in the overall trends and patterns.

Table A10. Cox regression output for the interaction model based on adult individuals. The table shows the hazard ratio (HR) indicating the estimated ratio of weekly vaccination rates in the intervention group compared to the synthetic control group in the 3 weeks following intervention.

Variables	HR	95% CI		p-value
		LCL	UCL	
Mobile vaccination unit (reference: no mobile vaccination unit)	1.83	1.72	1.95	<0.001
Age group (reference: 18-30 years old)				
(30,65]	2.16	2.05	2.29	<0.001
65+	1.49	1.08	2.06	0.017
Sex (reference: Women)				
Men	1.07	1.03	1.10	<0.001
Ethnicity (reference: White/White British)				
Asian/Asian British	0.83	0.71	0.98	0.027
Black/Black British	0.90	0.72	1.12	0.344
Mixed	0.77	0.62	0.96	0.021
Other ethnic groups	0.98	0.91	1.05	0.549
IMD tercile (reference: Least deprived)				
Intermediate deprivation	0.92	0.86	0.98	0.008
Most deprived areas	0.94	0.88	1.01	0.090
Chronic health conditions (reference: none)	0.97	0.95	0.99	0.013
Carer (reference: not carer)	0.67	0.56	0.80	<0.001
Social care receiver	1.02	0.79	1.30	0.894
Travel time by car to the nearest static vaccine centre (minutes)	1.04	1.04	1.05	<0.001
Interaction between age groups and mobile vaccination unit (reference: 18-30 years old with mobile vaccination unit)				
31-65 years old with mobile vaccination unit	0.65	0.61	0.69	<0.001
65+ years old with mobile vaccination unit	0.57	0.38	0.85	0.006
Interaction between ethnicity and mobile vaccination unit (reference: White/White British with mobile vaccination unit)				

Asian/Asian British with mobile vaccination unit	0.88	0.73	1.06	0.179
Black/Black British with mobile vaccination unit	0.70	0.54	0.90	0.006
Mixed with mobile vaccination unit	0.98	0.76	1.26	0.879
Other ethnic groups with mobile vaccination unit	0.98	0.91	1.07	0.670
Interaction between IMD tercile and mobile vaccination unit (reference: Least deprived with mobile vaccination unit)				
Intermediate deprivation with mobile vaccination unit	0.91	0.85	0.98	0.013
Most deprived areas with mobile vaccination unit	0.58	0.54	0.63	<0.001

Note: HR is hazard ratio. CI refers to confidence interval. LCL and UCL are the lower and upper confidence interval respectively.

Reporting checklist for cross sectional study.

Based on the STROBE cross sectional guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cross sectional reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
Title and abstract		1-2
Title	#1a Indicate the study's design with a commonly used term in the title or the abstract	1
Abstract	#1b Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction		4-5
Background / rationale	#2 Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	#3 State specific objectives, including any prespecified hypotheses	5
Methods		5-9
Study design	#4 Present key elements of study design early in the paper	5-9
Setting	#5 Describe the setting, locations, and relevant dates, including periods of	6-7

		recruitment, exposure, follow-up, and data collection	
1			
2	Eligibility criteria	#6a Give the eligibility criteria, and the sources and methods of selection of	7-9
3		participants.	
4			
5			
6		#7 Clearly define all outcomes, exposures, predictors, potential	7-9
7		confounders, and effect modifiers. Give diagnostic criteria, if applicable	
8			
9			
10	Data sources /	#8 For each variable of interest give sources of data and details of methods	5-6
11	measurement	of assessment (measurement). Describe comparability of assessment	
12		methods if there is more than one group. Give information separately	
13		for for exposed and unexposed groups if applicable.	
14			
15			
16			
17	Bias	#9 Describe any efforts to address potential sources of bias	8-9
18			
19	Study size	#10 Explain how the study size was arrived at	9
20			
21	Quantitative	#11 Explain how quantitative variables were handled in the analyses. If	5-6
22	variables	applicable, describe which groupings were chosen, and why	
23			
24			
25	Statistical	#12a Describe all statistical methods, including those used to control for	7-9
26	methods	confounding	
27			
28			
29	Statistical	#12b Describe any methods used to examine subgroups and interactions	9
30	methods		
31			
32			
33	Statistical	#12c Explain how missing data were addressed	9
34	methods		
35			
36			
37	Statistical	#12d If applicable, describe analytical methods taking account of sampling	
38	methods	strategy	
39			
40			
41	Statistical	#12e Describe any sensitivity analyses	9
42	methods		
43			
44	Results		9-12
45			
46	Participants	#13a Report numbers of individuals at each stage of study—eg numbers	
47		potentially eligible, examined for eligibility, confirmed eligible,	
48		included in the study, completing follow-up, and analysed. Give	
49		information separately for exposed and unexposed groups if applicable.	
50			
51			
52			
53	Participants	#13b Give reasons for non-participation at each stage	
54			
55			
56	Participants	#13c Consider use of a flow diagram	
57			
58	Descriptive data	#14a Give characteristics of study participants (eg demographic, clinical,	9-10
59			
60			

1		social) and information on exposures and potential confounders. Give	
2		information separately for exposed and unexposed groups if applicable.	
3			
4	Descriptive data	#14b Indicate number of participants with missing data for each variable of	8
5		interest	
6			
7			
8	Outcome data	#15 Report numbers of outcome events or summary measures. Give	10
9		information separately for exposed and unexposed groups if applicable.	
10			
11	Main results	#16a Give unadjusted estimates and, if applicable, confounder-adjusted	10-11
12		estimates and their precision (eg, 95% confidence interval). Make clear	
13		which confounders were adjusted for and why they were included	
14			
15			
16			
17	Main results	#16b Report category boundaries when continuous variables were categorized	11-12
18			
19	Main results	#16c If relevant, consider translating estimates of relative risk into absolute	11
20		risk for a meaningful time period	
21			
22			
23	Other analyses	#17 Report other analyses done—e.g., analyses of subgroups and	11-12
24		interactions, and sensitivity analyses	
25			
26			
27	Discussion		12-14
28			
29	Key results	#18 Summarise key results with reference to study objectives	12-13
30			
31	Limitations	#19 Discuss limitations of the study, taking into account sources of potential	13
32		bias or imprecision. Discuss both direction and magnitude of any	
33		potential bias.	
34			
35			
36			
37	Interpretation	#20 Give a cautious overall interpretation considering objectives,	13-14
38		limitations, multiplicity of analyses, results from similar studies, and	
39		other relevant evidence.	
40			
41			
42	Generalisability	#21 Discuss the generalisability (external validity) of the study results	13-14
43			
44			
45	Other		
46	Information		
47			
48	Funding	#22 Give the source of funding and the role of the funders for the present	15
49		study and, if applicable, for the original study on which the present	
50		article is based	
51			
52			
53			

None The STROBE checklist is distributed under the terms of the Creative Commons Attribution License CC-BY. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)